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Knowing the cost of delivering patient care is a mandatory first step as health care
leaders are tasked with reducing the cost of US health care. The Integrated Practice Unit (IPU)
model espoused by Michal Porter is a patient centered organizational framework whose tenets
support value driven care. University of Utah Health has developed a proprietary costing model
that gives them the ability to measure both costs and outcomes at the patient, provider, or in this
research case, IPU program level.
An interrupted time series (ITS) study design methodology is used to evaluate whether
there has been an immediate effect on HF patient costs and related indicators post
implementation of the HF IPU. The ITS pre/post analyses show an overall declining trend in
total HF costs, total HF technical costs, total HF professional costs, HF costs (total, surgical and
non-surgical), admissions, ED visits, and mean LOS. While VAD costs dropped initially, they
began to increase in the post intervention period. HF readmissions remained flat across the preand post periods. Statistically significant and declining trends were observed in HF surgical, and
non-surgical cost trends. While not all trends were statistically significant, they may be deemed
financially or clinically significant and worth further study.
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A Quantitative Review of Costs: Heart Failure Patients Before and After
Implementation of an Integrated Practice Unit Model at University of Utah Health
CHAPTER 1
INTRODUCTION
Novel models of health care delivery and partnerships, such as Accountable Care
Organizations (ACOs), bundled payment programs, and other integrated practice models,
have sprung up nationwide; however, we do not know their impact on health care costs or
in improving the health of a population. As health system leaders and providers strive to
deliver high-value care, we need to better understand, collect, and share patient cost and
outcome data (Porter, 2009).
The University of Utah Health system is one of a handful in the nation with a data
system that can track actual patient costs and quality outcomes, including both hospital
and professional expenses (Lee et al., 2016). The University of Utah Health (U of U
Health) team can quantify internal cost trends and evaluate the impact of interventions on
the cost of patient care using a value-driven outcomes (VDO) costing model. Due to this
unique ability, this research study includes a quantitative analysis of a program
evaluation of the Heart Failure (HF) Integrated Practice Unit (IPU) delivery model at U
of U Health, and compares differences in length of stay (LOS), hospital admissions,
hospital re-admissions and average patient costs for heart failure patients admitted to the
U of U Health before and after the implementation of the IPU. Specifically, the research
will explore if sharing patient cost and related outcome data with clinicians has an impact
on reducing those costs associated with the treatment of heart failure patients.
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Background and Need for Study
Knowing the cost of delivering patient care is a mandatory first step as health care
leaders are tasked with reducing the cost of US health care. Health spending in the US is
projected to increase on average 5.8 percent annually for the period 2014 – 2024, and
represents 19.6 percent of the gross domestic product (GDP) in 2014 (Keehan, Cuckler,
Sisko, & Madison et al., 2015). US health care spending as a percent of GDP is
significantly higher than other developed countries as shown in Figure 1 (The
Commonwealth Fund, 2016).
Figure 1. US Health Care Spending Trends

The Affordable Care Act (ACA) highlights the imperative to reduce the cost of
health care in the US, and challenges health care leaders to experiment with new models
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of health care delivery that improve the value of patient care. To evaluate these new
models of care and payment methods, clinicians and hospital organizations must
understand the actual costs and outcomes for individual patients with specific clinical
conditions (Lee et al., 2016). The research outlined in this proposal will examine cost
and cost related outcome trends in targeted heart failure patients.
Problem Statement
The Center for Medicare and Medicaid Services (CMS) has targeted heart failure
patients and their related health care expenses as a potential opportunity to reduce
national health care costs. In 2009, the estimated cost of treating heart failure patients in
the US was greater than $30 billion, and costs are expected to more-than-double in 15
years, as illustrated in Figure 2 (Bogaev, 2010; Voigt et al., 2014; “What is the cost…”,
2016).
Figure 2. Projection of Total Overall Costs for HF Patients in the United States

(Source: www.heartfailure.com, 2016)
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Acute heart failure (HF) is one of the most common reasons for overall hospital
admissions in the United States (US), and the largest cause of readmissions for both
medical and surgical patients (Sperry, B., Ruiz, G., & Najjar, S., 2014). One in four HF
patients are readmitted within 30 days of discharge (Bogaev, 2010). With each
hospitalization, the risk of HF mortality increases, as shown in Figure 3 (“What is the
cost…”, 2016). The high costs associated with the HF population make it ripe for
experimenting with care delivery models that reduce cost and improve or maintain
quality standards of care (Sperry, B., Ruiz, G., & Najjar, S., 2014).
Figure 3. Rising Risk of HF Mortality with Repeat Hospitalization

(Source: www.heartfailure.com, 2016)
This research study describes IPUs as a strategic redesign of how HF patients are
managed within U of U Health, and quantifies the early impact on health care costs and
other clinical outcomes. IPUs are defined using Michael Porter’s definition as a
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dedicated, multidisciplinary, team-based approach that focuses on comprehensive care
for the patient’s condition. The primary goal is to provide the highest value of care to the
patient, with value being defined as quality and patient satisfaction over cost (Porter &
Lee, 2013).
Objective of the Study
The University of Utah Health system is one of the few health care systems with a
data system that tracks patient costs and quality outcomes for both hospital and
professional expenses. That data is being shared with clinicians for further input on ways
to streamline costs and improve care (Appleby, 2014). This research study uses archival
data to compare U of U Health resource use and measure HF patient costs, observed to
expected length of stay (LOS), hospital admissions, hospital readmissions within 30 days,
and emergency department (ED) visits before and after IPU implementation. Heart
failure patients will be categorized into the following population segments to improve
comparability: Transplant, Ventricular Assisted Device (VAD), and Other Heart Failure
patients. The study objective is to measure the association of the HF IPU implementation
with HF patient costs and related hospital cost indicators. The findings will help clinical
teams identify what processes need to be in place to measure the effectiveness of patient
care for a targeted population.
Research Questions
This study compares resource use and measures cost for U of U Health HF
patients before and after implementation of an IPU business model using archival data.
The following questions have been addressed and will help inform administrators and
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clinicians as to how to measure and compare patient cost data and related hospital cost
indicators.
Research question number 1. Do HF patients post IPU implementation have
improved quality outcomes, such as shorter length of stay, and fewer HF hospital
readmissions than HF patients pre IPU?
Research question number 2. Do HF patients post IPU implementation have
fewer ED visits than HF patients pre IPU?
Research question number 3. Do HF patients post IPU have lower average
heart failure attributable cost-per-patient than patients pre IPU?
Hypotheses
The following research hypotheses will be examined. It is likely that the fidelity
in which the IPU was implemented and the time frames being examined will influence
early findings and conclusions.
Hypothesis H1. HF patient costs at U of U Health will begin to decline post IPU
implementation.
Hypothesis H2. HF admissions, readmissions, observed/expected LOS, and ED
visits will decline post IPU implementation.
Rationale for hypotheses. The above hypotheses are based off the following
central tenets of an IPU:
1. An IPU is organized around a medical condition or a set of closely related
conditions.
2. Care is delivered by a dedicated, multidisciplinary team of clinicians who devote a
significant portion of their time to the medical condition.
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3. Providers view themselves as part of a common organizational unit (IPU).
4. The team takes responsibility for the full cycle of care for the condition,
encompassing outpatient, inpatient, rehabilitative care, and supporting services
(such as social work, behavioral health, and nutrition).
5. Patient education, engagement, and follow-up are integrated into care.
6. The unit has a single administrative and scheduling structure.
7. A physician team captain or a clinical care manager (or both) oversees each
patient’s care process.
8. The team measures outcomes, costs, and processes for each patient using a
common measurement platform.
9. The providers on the team meet formally and informally on a regular basis to
discuss patients, processes, and results.
10. Joint accountability is accepted for outcomes and costs (Porter & Lee, 2013)
If these components of an IPU truly exist and incentives are aligned to improve
outcomes and cost, then HF costs should decline as clinical teams strive to maximize
patient value. Note that this study is a quantitative analysis of an IPU program evaluation
specifically measuring the impact on actual patient costs at U of U Health. While other
components of Porter and Lee’s (2013) IPU model may be referenced and described, they
will not be integral to the study.
The Integrated Practice Unit (IPU) Model at University of Utah Health
Beginning July 1, 2015, U of U Health implemented a HF IPU model similar in
structure and purpose as Porter and Lee’s IPU prototype referenced in their iconic article,
“The Strategy that will Fix Health Care” (2013). The purpose was to improve the value
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of care for this very large, costly HF population. This effort was considered a pilot, or
experiment, with the intent to measure the impact of engaging clinical teams more
directly in managing HF patient costs and outcomes by aligning care team governance,
clinical goals, and financial incentives. One must understand the HF IPU model at the U
of U Health to appreciate the context of this study’s research question, and whether the
implementation of an IPU model has led to a reduction of clinical costs. The following
section contains a comparison of the U of U Health IPU framework to those tenets
espoused by Porter and Lee, which serve as the rationale for the hypotheses. Porter and
Lee’s tenets are in bold.
It is important to note that the multidisciplinary team was comprised of stage C and D
heart failure cardiologists and surgeons, and does not include other cardiology providers,
primary care, rehabilitation or post discharge care. As such, the IPU team does not take
complete responsibility for the full cycle of care for HF conditions as noted in number 4.
This discrepancy in the model may have an influence on the study’s outcomes.
1.

An IPU is organized around a medical condition or a set of closely related

conditions. The HF IPU at U of U Health has been defined to include specific eligibility
criteria and includes a consistent methodology for identifying patients at the beginning of
their care. It is organized around the patients’ use of a multidisciplinary team focused on
improving the care and health of HF patients in an expanded cycle of care.
2.

Care is delivered by a dedicated, multidisciplinary team of clinicians who

devote a significant portion of their time to the medical condition. Care delivery and
management of the U of U Health HF population includes all patients who access a
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dedicated, multidisciplinary care team for HF. There are existing care pathways,
protocols, and care delivery processes in place.
3.

Providers view themselves as part of a common organizational unit (IPU).

The HF pilot is exclusive to a dedicated clinician team based on diagnosis and primary
physician provider. A multidisciplinary governance team comprised of HF cardiologists,
surgeons, nurses, midlevel, administration, and decision support staff meet regularly to
discuss costs, clinical outcomes, and care processes. This team holds the decision rights
for managerial decisions and is accountable for improving the value of patient care.
4.

The team takes responsibility for the full cycle of care for the condition,

encompassing outpatient, inpatient, rehabilitative care, and supporting services
(such as, social work, behavioral health and nutrition). To date, the HF IPU manages
only patient care that occurs at U of U Health. This approach includes many of the
patient’s care needs, but has yet to incorporate those services, providers, or caregivers in
other institutions outside of the U of U Health.
5.

Patient education, engagement, and follow-up are integrated into care. This

criterion is met for all patients who pursue follow up and education within the U of U
Health.
6.

The unit has a single administrative and scheduling structure. A dedicated

team of administrators including physicians, nurses, management, schedulers, and
decision support are focused on improving value for HF patients.
7.

A physician team captain or a clinical care manager (or both) oversees each

patient’s care process. The division chiefs of cardiology and cardiovascular services in
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conjunction with the administrative and care teams oversee the HF patient care processes,
many of which are documented in the electronic medical record.
8.

The team measures outcomes, costs, and processes for each patient using a

common measurement platform. The team measures the following outcomes, costs
and volume indicators for all HF patients admitted to the U of U Health:
•

Observed/expected (O/E) morbidity and mortality

•

New patient visits and scheduling lags

•

Patient satisfaction

•

Average total HF attributable costs (inpatient, outpatient, and professional)

•

Admissions

•

Emergency department (ED) HF visits

•

Readmissions within 30 days of HF admission

•

Inpatient HF market share

•

HF IPU contribution margin

•

Patient Reported Outcomes compliance

•

HF Patient encounter total cost of care (hospital and professional using the
VDO tool)

To date, systems are not in place to measure the longitudinal cost of care for patients, or
those costs that occur outside of the U of U Health.
9.

The providers on the team meet formally and informally on a regular basis

to discuss patients, processes, and results. The HF IPU team meets twice a month to
review metrics and discuss opportunities for care process improvement.
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Joint accountability is accepted for outcomes and costs. A single bottom line

has been established for professional and facility costs with incentives in place to align
improved contribution margin performance (Porter & Lee, 2013).
Figure 4 illustrates the essential characteristics for IPUs at U of U Health.
Figure 4. Characteristics Essential for IPUs at U of U Health

(Source: U of U Health Strategic Planning, 2015)
Lastly, a financial framework has been established at U of U Health to include a
minimum set of features required to align incentives around value. The economic model
must provide sufficient financial incentives to the IPU when success is achieved, and be
structured in a manner that allows for the evaluation and feasibility of the IPU financial
framework for both the health system and the IPU (Stephen Petersen, personal interview,
September 2015).
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Population
The study population has been defined to meet the following criteria:
•

Those patients whose initial HF encounter is organized around a patient’s medical
condition and includes an inpatient or outpatient HF diagnosis that is seen by one
of the following HF physicians at U of U Health: five HF cardiologists, two
cardiac surgeons, and supporting fellows and advanced practitioners. This team is
highly functional and advanced at direct patient care and achieving goals.

•

Once identified, any costs in subsequent HF encounters by this patient group will
be contained in the costing analysis.
The above HF population sample results in approximately 3,288 unique patients

and 53,000 visits over a three-year period (U of U Health Decision Support, 2016). The
patient population data as defined will be segmented into three HF sub-populations and
compared over a two-year period beginning July 1, 2014. The following codes were used
to designate a transplant, VAD, or other HF type of visit and includes both professional
and technical coding.
Transplant
CPT Codes
CPT Code
CPT Code Description
33935 Heart-lung transplant with recipient cardiectomy-pnumec
33945 Heart transplant with/without recipient cardiectomy
OR ICD Procedure Codes
ICD Procedure
ICD Procedure Description
02YA0Z0 Transplantation of Heart, Allogeneic, Open Approach
02YA0Z1 Transplantation of Heart, Syngeneic, Open Approach
37.51 HEART TRANSPLANTATION
02YA0Z2 Transplantation of Heart, Zooplastic, Open Approach
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Ventricular Assisted Device (VAD)
ICD Procedure Codes
ICD Procedure
02HA0RS
02HA0RZ
02HA3RS
02HA3RZ
02HA4RZ
02RK0JZ
02RL0JZ
02WA0JZ
02WA0QZ
02WA0RZ
02WA3QZ
02WA3RZ
02WA4QZ
02WA4RZ
37.52
37.53
37.54
37.6
37.6
37.62
37.63
37.65
37.66
37.68
39.65
5A02116
5A02216
5A0221D
5A15223

ICD Procedure Description
Insert of Bivent Ext Heart Assist into Heart, Open Approach
Insertion of Ext Heart Assist into Heart, Open Approach
Insert of Bivent Ext Heart Assist into Heart, Perc Approach
Insertion of Ext Heart Assist into Heart, Perc Approach
Insertion of Ext Heart Assist into Heart, Perc Endo Approach
Replacement of Right Ventricle with Synth Sub, Open
Approach
Replacement of Left Ventricle with Synth Sub, Open
Approach
Revision of Synthetic Substitute in Heart, Open Approach
Revision of Implant Heart Assist in Heart, Open Approach
Revision of Ext Heart Assist in Heart, Open Approach
Revision of Implant Heart Assist in Heart, Perc Approach
Revision of Ext Heart Assist in Heart, Perc Approach
Revise of Implant Heart Assist in Heart, Perc Endo Approach
Revision of Ext Heart Assist in Heart, Perc Endo Approach
IMPLNT TOTAL INT BIVENTRICULAR HEART
REPLCMT SYS
REPL/REPAIR THORACIC UNIT TOTAL REPL HEART
SYS
REPL/REPR OTH IMPL CMPNT TOT REPL HEART SYS
IMPLANTATON HEART & CIRCULATORY ASSIST
SYSTEMS
IMPLANT/INSERT BIVENTRICULAR EXT HRT ASSIST
SYS
INSERTION TEMP NON-IMPLANTABLE ECC ASSIST
DEVICE
REPAIR OF HEART ASSIST SYSTEM
IMPLANT SINGLE VENT EC EXT HEART ASSIST SYS
INSERTION OF IMPLANTABLE HEART ASSIST
SYSTEM
INSERTION PERQ EXTERNAL HEART ASSIST DEVICE
EXTRACORPOREAL MEMBRANE OXYGENATION
Assist with Cardiac Output using Other Pump, Intermittent
Assistance with Cardiac Output using Other Pump,
Continuous
Assist with Cardiac Output using Impeller Pump, Continuous
Extracorporeal Membrane Oxygenation, Continuous
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OR CPT Codes
CPT CODE
0048T
33946
33947
33948
33949
33952
33954
33956
33958
33962
33964
33975
33976
33979
33981
33982
33983
33988
33990
33991
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CPT CODE DESC
IMPLTJ VENTR ASSIST DEV XTRCORP PRQ T-SEPTAL
ECMO/ECLS INITIATION VENO-VENOUS
ECMO/ECLS INITIATION VENO-ARTERIAL
ECMO/ECLS DAILY MANAGEMENT EACH DAY
VENO-VENOUS
ECMO/ECLS DAILY MANAGEMENT EA DAY VENOARTERIAL
ECMO/ECLS INSJ OF PRPH CANNULA 6 YRS&OLDER
PERQ
ECMO/ECLS INSJ OF PRPH CANNULA 6 YRS&OLDER
OPEN
ECMO/ECLS INSJ OF CENTRAL CANNULA 6 YRS &
OLDER
ECMO/ECLS REPOS PERPH CANNULA PRQ 6 YRS &
OLDER
ECMO/ECLS REPOS PERPH CANNULA OPEN 6 YRS &
OLDER
ECMO/ECLS ECLS REPOS CENTRAL CNULA 6YRS &
OLDER
INSJ VENTRIC ASSIST DEV XTRCORP SINGLE
VENTRICLE
INSJ VENTRIC ASSIST DEV XTRCORP
BIVENTRICULAR
INSJ VENTR ASSIST DEV IMPLTABLE ICORP 1 VNTRC
RPLCMT XTRCORP VAD 1/BIVENTR PUMP 1/EA PUMP
PLCMT VAD PMP IMPLTBL ICORP 1 VENTR W/O
BYPASS
RPLCMT VAD PMP IMPLTBL ICORP 1 VNTR
W/BYPASS
INSERT LEFT HEART VENT BY THORACIC INC
ECMO/ECLS
INSJ PERQ VAD W/IMAGING ARTERY ACCESS ONLY
INSJ PERQ VAD TRNSPTAL W/IMAGE ART&VENOUS
ACCESS

Other Heart Failure
Includes all visits and associated codes when there were no codes for either
transplants or VADs as defined and the visit fit the population sample definition. Lastly,
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cost indicators are segmented and trended for both HF surgical and HF non-surgical in
order to more closely align patient type with outcomes.
Summary
Conditions have never been more favorable for structural redesign and
examination of innovative care delivery models focused on improving the value of health
care. The results of this program evaluation will add to the body of research knowledge
on the design of IPUs and their subsequent impact on costs, as well as inform health care
leaders of the challenges and lessons learned in managing a specific population, aligning
incentives and costs, identifying and measuring outcomes, and developing analytical
tools that support a more integrated, longitudinal treatment approach to improving
patients’ health.
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CHAPTER II
REVIEW OF THE LITERATURE
There is very little scientific research specific to studying the outcomes of Porter
and Lee’s IPU model; however, there is much to be learned about its fundamental
components, one of which is measuring outcomes and costs for every patient (Porter &
Lee, 2013). This study focuses primarily on a quantitative analysis of HF costs and
related hospital cost indicators post implementation of a similar IPU business model. As
such, the literature
review concentrates on
the following bodies of
research: US health
care costs,
transformative care
models, integrated care
delivery, integrated
practice units, common hospital costing methodologies, and interrupted time series
studies in a post study.
Literature Search Method
The literature search began with an exploration of the more recent works in the
PubMed database through the Eccles Health Sciences Library at the University of Utah.
The search focused primarily on years 1996 to current, since IPUs and value based health
care are relatively recent topics. The search site is integrated so that information in other
databases can be identified; thereby, incorporating literature from EBSCO Business
Source Premier, Scopus and other more business related search sites. Since much of
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economist Michael Porter’s value driven care and IPU work has been published in the
Harvard Business Review, Google Scholar’s search engine was used to collect those
relevant articles. Key search words included health care costs, integrated care, heart
failure, integrated practice units, heart failure costs, hospital costing models, value driven
outcomes, cost to charge ratios, time driven activity-based costing, Michael Porter,
interrupted time series, and segmented regression analysis in various combinations.
Electronically accessible documents were downloaded when available, and
abstracts were obtained. The literature collected also included key peer reviewed
reference articles, which were often added to the body of literature. All searches were
completed in August through November 2016 resulting in the discovery of approximately
80 articles and references relevant to this study. In addition, other opportune information
was obtained from various expert websites, such as CMS.gov, and through expert content
received during personal interviews. The remainder of this section summarizes the
significant findings and subsequent learnings from this comprehensive literature search.
Value Based Health Care
There is overwhelming evidence that an opportunity exists to improve the value
of health care in the US (DiSesa & Kaiser, 2015; IOM, 2001; James, 2007; Kohn,
Corrigan, & Donaldson, 1999; Wennberg, 1999). To facilitate improved cost control,
quality and access, US health care delivery is moving from a primarily fee-for-service
payment delivery into various integrated, risk based models, such as accountable care
organizations (ACOs), patient centered medical homes (PCMHs), bundled payments for a
defined service, and integrated practice units (IPUs) (Herzingler, Schleicher, & Mullangi,
2016). The Department of Health and Human Services (HHS) is focusing its energies on
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using incentives to motivate higher value care, tying reimbursement through alternative
payment models that reward value, and paying greater attention to population health and
coordination of care across settings (Burwell, 2015).
In the transition from volume to value focus, health system leaders and providers
will need to develop different care team models focused on the patients’ continuum of
care and service needs. This is a significant change in the medical culture and the
traditional one on one relationship between the provider and patient. Physician
leadership is essential to be effective at reorganizing and executing under this new order.
(Porter and Teisberg, 2007; Herzlinger, Schleicher, & Mullangi, 2016; Weisenberg,
2016).
In addition to the cost, quality, and patient experience tenets of value based care
and the “Triple Aim” routinely referenced in the literature, the Institute for Health Care
Improvement in a seven-year study of the “Triple Aim” identified three main elements
for successful population management: identifying the relevant population, creating a
governance structure, and articulating a clear purpose for the work. These foundational
beliefs are consistent with Porter & Lee’s central tenets of an IPU in achieving high value
for the patient (Whittington, Nolan, Lewis & Torres, 2015; Porter, 2010).
Another important aspect of successful value based care is aligning incentives and
funds flow mechanisms to support effective patient care coordination. Health care funds
flow and financial partnership arrangements are complex, and beyond the scope of this
study; however, it remains essential that organizations understand their true patient costs
to distribute revenues or share in savings associated with high value patient care (Bird,
Reney, & Ross, 2015).
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All the above has led to an unprecedented interest in innovative, integrated
delivery models focused on improving patient value and lowering US health care costs.
Integrated Care Delivery and Other Transformative Practice Models
At the core of this
proposed value transformation is
changing the way clinicians are
organized to deliver care and the
importance of physicians
engaging with their patients in
this effort (Porter & Lee, 2013).
Several health care systems have
experimented with IPU models including MD Anderson, Cleveland Clinic and others.
MD Anderson in Texas organizes patient care around the type of cancer being treated,
with all the applicable specialties collocated in a dedicated practice facility. The
Cleveland Clinic has organized IPUs in cardiac and eye care (Porter & Teisberg, 2006).
To understand the impact of these models, it is essential to be able to measure
both risk adjusted, clinical outcomes and actual care delivery costs over a defined period.
A fundamental conceptual framework espoused by Porter is that improving clinical
outcomes results in reduced costs. However, most health care systems and physicians do
not have a good understanding of their actual health care delivery costs for a patient
population, nor do they have incentives to improve value (Algorithms for Innovation,
2013; Kaplan & Porter, 2011; Porter & Teisberg, 2007). A common theme in the
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literature is the temptation to look at only the quality or outcomes side of the value
equation (Pollock, 2008).
In a recent systematic review on integrated models of health care delivery, the
authors (Mitchell et al., 2015) note an urgent need for future research and quantitative
study of complex, chronic disease delivery models, and their impact on outcomes, quality
of life and resource effectiveness. Most of the literature and study to date highlight
advances in care delivery processes, such as communications and interdisciplinary team
work, and focuses on improvement in clinical outcomes (Bogaev, 2010; Mitchell, et al.,
2015). Researchers reinforce the importance of coordination between health
professionals and better integration of treatment with preventative, rehabilitation and
disease management, which is believed will lead to improved clinical outcomes and cost
(McKay and Wieck, 2014; Porter & Teisberg, 2007). However, there continues to be a
strong need for research studies that measure both clinical outcomes and their associated
costs; the current state of available cost information is abysmal (Porter & Teisberg,
2007).
Considering reimbursement changes and readmission penalties emphasizing care
across the continuum, several systems have developed multidisciplinary, care
coordination models that they hope will help manage costs and improve patient health.
As example, Parkview Heart Institute developed a three-phased approach to reduce
readmissions that included 1) improving inpatient care and transitioning the patient post
discharge, optimizing the use of tele-management services, and working with primary
care physicians to promote early interventions and avoid admissions. Their efforts
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showed significant reductions in readmission, length of stay, and HF mortality (Advisory
Board, 2012).
MD Anderson has also experimented with value based care and implementing an
IPU model for the treatment of cancer disease specific clusters or multidisciplinary care
centers. In their experience, researchers note that much better measurements of outcomes
and true costs are critically needed (Porter & Teisberg, 2006).
Others are also developing innovative approaches around managing the increasing
burden of chronic diseases, such as diabetes, cancer, and cardiovascular disease. These
programs are very much in their infancy and face significant barriers around patient data
sharing, payment mechanisms that are not aligned with the delivery of value based care,
and a cultural mindset based on a history of professional autonomy in clinical practice
(Dunbar-Rees, Panch, & Dancy, 2013).
Significance of Heart Failure Costs
HF has a major effect on patients’ health status, whether it be symptom burden,
functional status, or quality of life. Not only is it expensive, but it remains the leading
cause of disability, hospitalization and death in the US (Bekelman, et al., 2015). There
have been numerous studies experimenting with heart failure care delivery models
focused on the HF population. The National Health Service (NHS) in 2013 published its
Cardiovascular Disease Outcomes Strategy with the primary recommendation to
clinically manage cardiovascular disease as a single grouping of conditions to improve
patient outcomes, coordination of care, and reduce costs (Dunbar-Rees, Panch, & Dancy,
2014). The Texas Heart Institute in 2010 sponsored a white paper highlighting measures,
such as communicating, evaluating from a business perspective, aligning physicians and
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hospitals, and enhancing support services, to ensure VAD therapy was affordable and
accessible (Bogaev, 2010). Parkview Heart Institute in 2011 developed a
multidisciplinary project to coordinate heart failure care and reduce associated
readmission by improving inpatient care and the post discharge process, optimizing telemanagement in continuum of care and working with primary care physicians to prevent
care (Advisory Board, 2012). These are just a few examples of recent studies that hoped
to contribute knowledge towards improving the value of care for heart failure patients.
However, there is still not clear consensus as to what interventions demonstrate improved
health status or lead to sustainable reductions in cost.
In a large collaborative, researchers explored the effectiveness of a patient
centered disease management (PCDM) intervention to improve the health of HF patients.
Unfortunately, this multisite randomize trial did not demonstrate improved patient health
status and patient costs were not analyzed (Bekelman, et al., 2015).
Episode based payments or bundled payments are at the forefront of national
discussion on combating rising health care costs. In August 2016, CMS announced the
addition of Acute Myocardial Infarction (AMI) and Coronary Artery Bypass Graft
(CABG) to Medicare’s bundled payment programs (CMS, 2016). While this bundle is
not directly related to HF patients, cardiovascular care is an arena in which bundled
payments may become increasingly visible and be most impactful. An interesting debate
is emerging as to whether bundled payment approaches are just another form of silo care
around a disease condition, such as Geisinger’s focused factory delivery model, versus an
integrated approach that leads to real improvement in patient value.

Early evidence on

the impact of bundled payments on health care costs remains inconclusive. In addition,
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there is very little evidence based research in the literature to support these alternative
payment models (Shih, Chen & Nallamothu, 2015).
Understanding the Cost Side of the Value Equation
Determining value in health care as defined as outcomes over unit costs is
dependent upon accurately capturing and measuring those unit costs (Kaplan et al.,
2014). Accurately assigning costs is challenging and approaches vary depending on
stakeholder perspectives, such as the health care system, payer, patient or society (Lee et
al, 2016). To access profitability under existing payment systems, most organizations use
one of three costing methodologies: ratio of cost to charges (RCC), relative value unit
(RVU) or the activity based costing (ABC). Some of these costing methods have proven
to be more reliable than others; however, their external reliability is limited due to each
organizations’ unique cost structure (West, Balas, & West, 1996).
Management accounting in health care has experienced somewhat of an evolution
from estimated cost determination models to those that are focused on creation of value
(Esmalifalak, Albin, & Behzadpoor, 2014). For these reasons, understanding the costing
methodologies, and their strengths and weaknesses becomes an integral component of
this research analysis. Any research model’s usefulness is largely predicated upon the
reliability of its output (Esmalifalak, Albin, & Behzadpoor, 2014).
Accurate cost measurement in health care is challenging because a patient’s
treatment involves so many different types of resources. To measure true costs, these
shared resource costs need to be attributed to each patient based on their actual resource
use (Kaplan & Porter, 2011; Porter, 2010). This literature search seeks to understand and
compare popular and proven hospital costing models, including the Value Driven
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Outcomes (VDO) costing model used at U of U Health, the Cost to Charge ratio method
(RCC), and Time Driven Activity – Based costing method (TDABC).
Value Driven Outcomes. A pragmatic, modular and extensible software
framework is used to capture and allocate clinical care costs to individual patient
encounters. This Value Driven Outcomes (VDO) software was developed by U of U
Health, and has been shown to accurately reflect organizational cost accounting, as well
as support the measurement of quality, outcome and value (Kawamoto, et al., 2015). The
software is built on existing organizational cost measurement and analytical capabilities
to establish robust analytics for improving outcomes relative to costs. A key component
of the methodology is creating a timely process for reporting and analysis of patient
centered cost and outcomes data (Kip Williams, personal interview, 2014). The ability to
quantify costs at the individual patient level is necessary in transforming health care from
episodic, volume oriented care to patient centered, value based care (Lee et al., 2016).
The scope of VDO costs include actual inpatient and outpatient costs for both the
facility and the professional expenses; therefore, it is crucial that physician leadership
understand the data methodology. The facility costing is derived from clinical data
sources and billing data, which is based off acquisition and utilization costs whenever
available. The costing models applied include actual, time based, and equal distribution
costing methodologies depending on the output being measured. In summary, it is a fully
absorbed costing process that is reconciled to the organization’s general ledger. The VDO
approach to assigning direct costs is contained in Table 1. (Lee et al., 2016).
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Table 1. VDO Approach to Assigning Costs
Table 1. Value-Driven Outcomes Approach to Assigning Direct Cost for a Given Area
Area of Cost
Sources of Cost Data
Method of Cost Assignment
Facility utilization1
All facility-paid general
For inpatient units, time the
ledger expenses for operating patient spent on the unit; for
a clinical unit where patients
outpatient clinics, average
can be located (e.g.,
facility expenses for a visit to
emergency department,
that clinic
cardiology inpatient ward,
family medicine clinic),
including nursing, space, and
equipment costs
Imaging2
All facility-paid general
Time-based for patient use
ledger expenses for operating
an imaging unit (e.g.,
magnetic resonance imaging
unit, computed tomography
unit), including equipment,
space, and technician costs
Laboratory testing3
Existing contracts
Actual patient use
Therapy services
All facility-paid general
Patient use of services as
ledger expenses associated
identified from billing charges
with operating a therapy
service (e.g., respiratory
therapy, physical therapy),
including personnel and
equipment costs
Medications administered3
Acquisition costs
Actual patient use
Supplies
Acquisition costs
Actual patient use
Professional services
Physician human resource
wRVU billing by physician
costs for clinical care, as well
as other general ledger
clinical expenses paid by
physicians and their
representatives (e.g., medical
assistant costs paid by
medical group), grouped by
unit (e.g., cardiology)
Abbreviation: wRVU, work relative value unit.
1Costs related to maintenance, renovation, and new construction are considered indirect costs
and are not included in the direct costs.
2General ledger expenses for clinical units refer to all expenses recorded in the organization’s
complete record of financial transactions.
3Outpatient laboratory, pharmacy (medications administered), and imaging costs include only
that care delivered at the University of Utah.
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A detailed description of the VDO methodology, including sample reports, can be found
in the Journal of American Medical Informatics as referenced (Kawamoto, 2013).
The strength of the VDO methodology is that it allows for comprehensive study
of both sides of the value equation – cost and quality outcomes – and includes facility and
professional costs at the patient, episode of care, and even provider levels. The tool can
be used in quality improvement, clinical outcome, and cost effectiveness studies to help
understand practice variability and clinical cost effectiveness. The primary limitation is
that it is proprietary to University of Utah Health and has not yet been replicated
elsewhere (Kawamoto, 2013).
Cost to Charge Ratio. Historically, many health care leaders and managerial
decision makers have estimated hospital costs by using RCCs applied to a unit of service.
While this methodology may work well when examining average costs across a diagnosis
related group (DRG) or other broad units of service, it has not proven to be a good
methodology for determining costs associated with a particular patient. This is because
there is too much variability in costs within departments, and patients consume resources
across many different departments, which then exacerbates the error of the averages used
in RCCs. Hence, the level of granularity for cost analysis is precisely affected by how an
organization captures utilization (Cary Martin, U of U Health, personal interview).
Shwartz, Young and Siegrist collected and studied cost data on seven hospitals
comparing Relative Value Unit (RVU) based costing with RCCs. There was a high
correlation between the two methodologies in comparing individual patient costs.
However, their study showed that 30% of the DRGs had an error greater than 10% using
RCC estimated costs compared to RVU estimated costs (1995). In another study of a
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Midwest renal clinic, researchers found RCCs to be the least accurate measure of cost
when compared to RVU and ABC models (West, Balas, & West, 1996). These small
inquiries exemplify the need for further study and exploration of accurate costing models
in health systems. While RCC may not be the most accurate costing method, it could be
helpful when comparing to external information where other common cost collection
metrics are not available.
Time Driven Activity – Based Costing (TDABC). Health care economists at
Harvard Business School developed this novel costing strategy in order to more
accurately estimate true cost. TDABC relies on managerial cost estimates of resources
utilized in each encounter, product or patient using multiple time drivers that can be
applied more precisely than traditional activity based costing. The TDABC model was
developed to help health care leaders and managers understand clinical costs and identify
ways to improve value in an era of shared risk for costs (Kaplan, 2015) (West & Balas,
1995).
As example, Cleveland Clinic partnered with the Harvard Business School to
determine whether the TDABC methodology would improve the accuracy of costs,
enhance value opportunities, and help drive improvements in practice for heart valve
procedures. They compared the TDABC design to their current RVU cost allocation
methodology in evaluating the strengths and weaknesses of each. The researchers found
that the TDABC enabled them to gain additional insights into their costing technique, and
improve clinical processes (Donovan, Hopkins, Kimmel, Koberna & Montie, 2014).
TDABC has been shown to be a useful tool to measure costs and value in clinical care.
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Knowing and understanding actual health care costs for an episode of care is
becoming increasingly important for health care leaders, as the financial risk for health
care shifts more to the providers (Kaplan, 2015). Contrasting VDO costs with those
found in other costing methodologies may provide useful insights and perhaps improve
the external reliability of this study.
Summary
In conclusion, conditions have never been more favorable for structural redesign
and examination of innovative care delivery models focused on improving the value of
health care. Integral to improving value is measuring and understanding actual costs at
the individual, patient level. The IPU is a patient centered organizational framework
whose tenets support population health for specific conditions, and value driven care.
One of the central precepts of the IPU is that the team measures outcomes, costs and
processes using a common measurement platform. To date, there are very few health
systems that can measure actual patient care delivery costs that include both hospital and
professional expenses for inpatient and outpatient care.
U of U Health has developed a proprietary costing model that gives them the
ability to measure both costs and outcomes at the patient, provider, program, or in this
research case, IPU level. Hence, the results of this quantitative analysis of a HF IPU
program evaluation will add to the body of research knowledge on the design of IPUs and
their subsequent impact on costs, as well as inform health care leaders of the challenges
and lessons learned in managing a specific population, aligning incentives and costs, and
developing analytical tools that support a more integrated, longitudinal treatment
approach to improving patients’ health.
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CHAPTER III
METHODOLOGY
Study Design
The design of the study is a quantitative analysis of a program evaluation using
archival data from University of Utah Health. An interrupted time series (ITS) study
design methodology is used to evaluate whether there has been an immediate effect on
HF patient costs post implementation of the HF IPU. The ITS is one of the strongest,
quasi – experimental approaches for evaluating the effects of population level health
interventions that are implemented at a point in time. One of the most common quasi –
experimental design approaches is the Comparison Group Pretest/Posttest design. The
ITS pre/posttest design is often used to test statistical change in an outcome rate in the
time periods before and after implementation of a program designed to change the
outcome (Wagner, Soumerai, Zhang, & Ross – Degan, 2002; Bernal, Cummins, &
Gasparrini, 2016).
Statistical modeling using regression analysis assures that post study HF patients
have similar severity and match. Multivariable statistical modeling controls for
differences in patient characteristics. Segmented regression analyses are then used to
evaluate whether the observed changes reflect random variation or a true change (Shi,
2008; Penfold & Zhang, 2013; Fretheim & Tomic, 2015).
The strengths of the ITS design include its wide applicability in evaluating the
effectiveness of interventions absent a randomized control study, the ability to study
outcomes data using population level data, clear graphical or visual representation of the
data and results, and use of statistical control processes to correct for changes that might
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have occurred without the intervention (Penfold & Zhang, 2013; Fretheim & Tomic,
2015).
The ITS study design limitations include the short-term view of outcomes, which
may not reflect the full potential or impact of the program, and an assumption of linearity
when longer term changes may not be linear. The segmented regression analysis
approach aggregates individual level data, and does not necessarily reflect individual
level characteristics or covariates (Wagner, Soumerai, Zhang, & Ross – Degan, 2002;
Jaewhan Kim, personal interview, 2016). To minimize these limitations, the research
design enforces statistical regression models, consistency in methods, and employs other
controls to improve external validity.
Hypotheses
A retrospective, quantitative analysis of an IPU program evaluation using archival
data from U of U Health will be conducted to analyze its impact on HF costs. An
uncontrolled, pre and post, longitudinal, and observational study design was implemented
to measure costs from 2014-2016. An interrupted time series (ITS) regression with a
design methodology was used with aggregated outcome variables to evaluate whether
there was an immediate effect on HF patient costs/utilization post implementation of the
HF IPU.
𝑌𝑌𝑡𝑡 = 𝛼𝛼 + 𝛽𝛽1 𝑇𝑇 + 𝛽𝛽2 𝑋𝑋𝑡𝑡 + 𝛽𝛽3 (𝑇𝑇 ∗ 𝑋𝑋𝑡𝑡 )

, where Y is the outcome at time t, 𝛼𝛼 is the baseline level in the outcome at T=0,

𝛽𝛽1 represents a coefficient related to changes in the outcome over time, T is the time
variable indicating time since the study starts, 𝑋𝑋𝑡𝑡 is an indicator variable (0 before

intervention and 1 after intervention), 𝛽𝛽2 is a coefficient indicating the level change after
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intervention, 𝑇𝑇 ∗ 𝑋𝑋𝑡𝑡 is an interaction variable, and 𝛽𝛽3 indicates the slope change after
intervention (Bernal, Cummins & Gasparrini, 2016).

This research study compared U of U Health resource use and measured HF
patient inpatient costs, observed to expected length of stay (LOS), hospital admissions,
hospital readmissions within 30 days, and Emergency Department (ED) visits before and
after IPU implementation using archival data. Heart failure patients were categorized
into the following population segments to improve comparability: Transplant,
Ventricular Assisted Device (VAD), and Other Heart Failure patients. Analyzing HF
patients as a single group blends episode of care and population health data for those
patients who received care at U of U Health (James Fang, personal interview, February
14, 2017).
The primary aim of this study was to address the following research questions in
order to inform administrators and clinicians as to how to measure and compare patient
cost data and related hospital cost indicators.
Research question number 1. Do HF patients post IPU implementation have
improved quality outcomes, such as shorter length of stay, and fewer hospital admissions
and readmissions than patients pre IPU?
Research question number 2. Do HF patients post IPU implementation have
fewer ED visits than HF patients pre IPU?
Research question number 3. Do HF patients post IPU have lower average
heart failure attributable cost-per-patient than patients pre IPU?
These questions helped to inform the following hypotheses:
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Hypothesis H1. HF patient costs at U of U Health will decline post IPU
implementation.
Hypothesis H2. HF admissions, readmissions, observed/expected LOS, and ED
visits will decline post IPU implementation.
Population and Sample
All Advanced HF patients meeting the following criteria were included in both
the post study samples: A patient who 1) identified with an initial HF diagnosis
encounter either as an inpatient or outpatient in the U of U Health system and was treated
by specific cardiology and cardiovascular providers, and 2) any subsequent HF
encounters incurred by this patient group for the fiscal years 2014 – 2016. The U of U
Health fiscal year is July 1 – June 30th. The diagnostic codes for inclusion are outlined
in Appendix A. In addition, the patient population count is illustrated in Figure 5 (U of U
Health Enterprise Data Warehouse, 2016.
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Figure 5. U of U Health HF Population Sample Counts
________________________________________________________________________

Unique MRN's that had a
visit to one of the providers
MRNs
Unique count of MRN'S
as the identified primary included in With identified diagnosis
performing or attending
the study
codes
provider
3288
36059
(3)
4771
(2)
(1)

1 – Contains a list of all distinct Medical Record numbers (MRNs) where patient was
seen by a designated provider. The designation was applied to 8 different providers and
the discharge date needed to have occurred after or equal to July 1, 2012.
2 – Contains a list of distinct MRNs where patient received a specifically defined
diagnosis code either from technical or professional billing, and the discharge date
needed to have occurred after or equal to July 1, 2012.
3 – Contains a list of distinct MRNs where patient belonged to the list of defined
diagnosis codes and was seen by one of the designated providers to include in the dataset.
________________________________________________________________________
De-identified patient data was used. The Medical University of South Carolina
(MUSC) and University of Utah Institutional Review Boards (IRBs) classified the study
as non-human subjects research.
Definition of Variables
A definition of cost outcome variables is contained in Table 2. These variables
were collected for all subgroups of the HF population: Transplants, VADs and Other HF
patients, excluding Veteran Administration patients, using the U of U Health VDO
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costing model. HF readmission inclusion criteria are illustrated in the 2 x 2 box in Table
3.
Table 2. U of U Health Cost Outcome Variables
Cost Indicators
Cost Per Procedure:
Transplants and VADs
Inpatient Average Discharge
Costs: Other HF
Observed to expected (O/E)
Length of Stay (LOS):
Transplants, VADs and Other
HF
HF Volume: Transplant, VAD,
and Other HF

Definition
VDO Model
Sum of total direct costs divided by the total
count of transplants or VADs
Sum of total direct cost divided by the total count
of inpatient visits for HF patients only
Sum of observed LOS divided by expected LOS
for all inpatient visits; expected LOS determined
by Vizient* clinical database
Counts of total number of discharged transplants,
VAD procedures, and HF new patient visits
(NPVS)
Count of number of ED visits, regardless of last
discharge date
Sum of the number of Vizient* 30 day readmits
divided by the number of inpatient discharges

ED Visit Counts: Transplants,
VADs, and Other HF
HF 30 Day Readmission Rates:
Transplants, VADS, and Other
HF
*Vizient is the clinical benchmarking database used by most academic medical centers
and defines 30-day all cause readmission rates for adult, non-OB patients as the
percentage of patients within certain service lines who return to the hospital for any
reason within 30 days of discharge from the prior (index) admission (U of U Health
Decision Support, 2016)
Table 3. HF Readmission Inclusion 2 x 2 Box
HF Readmits
HF Admits
Non – HF Admits

Non – HF Readmits
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The predictor variable was the implementation of the IPU business model as
previously defined beginning July 1, 2015. Other independent variables collected and
included in the descriptive statistics and regression analyses include age at admission, deidentified medical record number, gender, race and ethnicity, zip code, block group, ICD10, CPT, ICD Procedure Codes, DRG, date of service, severity index (CMI) and
Hierarchical Clinical Categorization (HCCs). A complete list of variables, codes and
corresponding queries are contained in Appendix B.
Data Set Description and Structure
A finer data structure in long format was used to model the ITS regression
analysis. A data set sample with corresponding variables and properties is illustrated in
Figure 6.
Figure 6. HF Population Data Structure Example (Screenshot)
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The data comes from multiple health care information systems and was obtained from the
U of U Health enterprise data warehouse (EDW). All patient data was de-identified
using surrogate identification numbers. Cost data was adjusted annually for inflation
using the medical consumer price index (CPI) and will be presented in 2016 dollars
(Bureau of Labor Statistics, 2016). A finer data structure in long format was used in
preparing the data for regression analysis using Stata version 14.0 (StataCorp).
Data Analysis
The ITS regression analysis identifies and compares cost and outcome
data one year prior implementation of the HF IPU, and one-year post implementation
using data collected from July 1, 2014 through June 30, 2015 as the timeframe before
implementation, and July 1, 2015 through June 30, 2016 as the data collection period post
implementation of the HF IPU. The data was set up in a long file format where each row
is one time point per subject, or in this case per visit (Grace-Martin, 2016). Both
professional and technical costs were aggregated based on primary visit. Missing values
were excluded where there were either invalid visit numbers or duplicate visits.
In addition, outliers were adjusted to remove those representing the top .10
percent of all HF patient costs including VADs and Transplants. Stata version 14.0
(StataCorp) was used for the analysis whereby results are interpreted as follows:
_t = the slope of the cost variable before intervention
_x0 = the change in cost immediately after the intervention
_x _ t0 = the difference in slope of the cost between the pre and post intervention
A p-value ≤ 0.05 will be interpreted as statistically significant not correcting for multiple
comparisons. Cumby – Huizinga actest for autocorrelation was completed on all
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pre/post data comparisons and was not statistically significant in all cases (Baum &
Schaffer, 2013).
All cost data trends are normalized and adjusted for mean age, percent male,
percent white, and the mean CCI in the regression analysis. Cost data was normalized or
indexed based on the following equation and scaled to a range of (0,1) (Grus, 2015):
Normalized cost = (cost – minimum cost)/ (maximum cost – minimum cost)
A detailed description of the data set and statistical queries can be found in Appendices D
and E.
Limitations
Key limitations of the study include the relatively short term view of outcomes,
whereby the IPU model and related systems may not have reached its full power to show
the true impact on cost or cost trends. Also, there is very little external reliability since
the study includes archival data from just one hospital and compares average costs using
a proprietary costing model (Shi, 2008; Rachel Hess, U of U Health, personal interview,
2016). However, in a quasi-experimental design such as this, an interrupted time series
(ITS) with segmented regression analysis is one of the strongest research designs used to
examine the impact on a population from programmatic interventions implemented at a
point in time (Wagner, Soumerai, Zhang, & Ross – Degan, 2002; Bernal, Cummins, &
Gasparrini, 2016).
In addition, there are inherent limitations in the ITS methodologies, including but
not limited to, over-dispersion of time series data, autocorrelation, seasonal trends, and
time varying confounders (Bernal, Cummins, & Gasparrini, 2016). Much of this will be
controlled through statistical analysis. Lastly, results could be due to confounding factors
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or spurious events; and therefore, are not causal but correlated effects. There is also
possible instrumentation and researcher bias that may influence the results and
conclusions (Shi, 2008).
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CHAPTER IV
RESULTS

The ITS pre/post analyses show overall declining trends in total HF costs, total
HF technical costs, total HF professional costs, HF costs (total, surgical and nonsurgical), admissions, ED visits, and mean LOS. While VAD costs dropped initially,
they began to increase in the post intervention period. HF readmissions remained flat
across the pre and post periods. HF surgical and non-surgical costs have seen
statistically significant declines post implementation of the HF IPU. While most of the
other trends are not statistically significant, they are trending in the right direction and
might become statistically significant over time.
Population Characteristics
As previously defined in the methodology chapter, the population includes all
advanced HF patients meeting the following criteria: a patient who 1) identified with an
initial HF diagnosis encounter either as an inpatient or outpatient in the U of U Health
system and was treated by select cardiology and cardiovascular providers, and 2) any
subsequent HF encounters incurred by this patient group for the fiscal years 2015 – 2016.
Fiscal year 2014 data was eliminated due to inconsistencies in the data collection
methodology with the other years, resulting in fewer number of patients studied. Other
population characteristics obtained included age, gender, race, and the Charleston Comorbidity index. A complete list of the data set and associated variables is contained in
Appendix D.
Based on their coefficient of variations, there was less than a five percent variance
across aggregated monthly patient characteristics in mean age, percent male, percent
white, and mean CCI; therefore, the study did not test for statistical significance. On
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average, there were approximately 656 patients and 1,521 visits each month. The
average aggregate monthly patient age was 63 years old, 66 percent of the patients were
male (44 percent female), 86 percent of the patients were white (14 percent other), and
the average clinical severity index was 5.13. A summary of the data set aggregated by
month is listed in Table 4.
Table 4. Summary of Population Characteristics Aggregated by Month Tables 1-2
Summary Table 1
Months
-12
-11
-10
-9
-8
-7
-6
-5
-4
-3
-2
-1
0
1
2
3
4
5
6
7
8
9
10
11
Average

Total
Patients
580
608
612
676
597
624
624
694
724
711
699
711
748
721
782
630
610
614
576
618
666
620
663
639
656

Visits
1340
1390
1382
1652
1317
1510
1506
1616
1822
1649
1679
1751
1820
1706
1887
1408
1326
1409
1219
1341
1585
1409
1391
1386
1521

Age
63.00
63.00
63.00
64.00
63.00
64.00
64.00
63.00
63.00
63.00
64.00
64.00
64.00
64.00
63.00
63.00
62.00
62.00
61.00
62.00
62.00
61.00
61.00
62.00
62.83

Percent
Male
67.24
66.61
65.20
63.46
64.99
63.94
64.74
67.15
64.09
64.56
64.66
66.81
64.30
65.05
66.75
64.76
67.54
68.57
67.01
66.83
67.57
69.03
67.12
70.74
66.20

Percent
White
86.72
86.02
86.27
87.43
85.59
87.02
86.70
87.03
84.94
86.08
86.98
87.48
86.23
85.71
86.57
85.40
83.61
83.88
83.51
84.63
84.83
85.81
83.56
83.41
85.64

Avg CCI
5.10
5.14
4.95
4.99
5.28
5.03
5.21
4.98
5.15
5.10
5.17
5.17
5.17
5.17
4.98
5.15
5.10
5.38
5.21
5.17
5.14
5.10
5.12
5.15
5.13
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Summary Table 2
Norm
Total
Months
Cost
-12
0.68
-11
0.63
-10
0.47
-9
0.54
-8
0.62
-7
0.93
-6
0.85
-5
0.55
-4
0.69
-3
0.46
-2
1.00
-1
0.43
0
0.67
1
0.63
2
0.67
3
0.93
4
0.50
5
0.98
6
0.50
7
0.67
8
0.81
9
0.67
10
0.71
11
0.00
Average
0.65

Norm
Tech
Cost
0.64
0.59
0.44
0.53
0.61
0.93
0.82
0.51
0.68
0.47
1.00
0.42
0.67
0.64
0.66
0.92
0.50
0.99
0.50
0.67
0.80
0.68
0.72
0.00
0.64

Norm
Prof
Cost
0.90
0.91
0.67
0.59
0.63
0.88
1.00
0.78
0.74
0.36
0.96
0.46
0.62
0.56
0.73
0.98
0.50
0.84
0.50
0.63
0.80
0.60
0.62
0.00
0.68
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Avg
LOS
8.29
8.65
9.07
7.72
8.06
9.08
9.29
8.22
10.04
7.69
9.33
8.09
8.64
9.21
9.48
8.93
6.59
10.10
7.05
8.71
6.75
8.14
8.79
5.72
8.40

ED Visits Admits Readmits
1000
17.24
18.09
21.24
13.31
21.78
22.44
28.85
28.82
27.62
30.94
21.46
15.47
12.03
22.19
34.53
12.70
11.48
16.29
17.36
14.56
10.51
20.97
16.59
21.91
19.93

1000
162.07
171.05
130.72
159.76
139.03
169.87
171.47
162.82
132.60
126.58
171.67
143.46
140.37
141.47
154.73
160.32
165.57
154.72
161.46
155.34
168.17
143.55
131.22
118.94
151.54

1000
0.16
0.18
0.15
0.31
0.16
0.26
0.21
0.22
0.11
0.19
0.21
0.19
0.19
0.21
0.18
0.16
0.21
0.19
0.22
0.17
0.16
0.24
0.22
0.18
0.19

Data Analysis
The remainder of this section illustrates trends for each of the cost and outcome
variables studied. Study results and related detail are organized within the context of the
hypotheses. All ITS regression tables with autocorrelation analysis are contained in
Appendix E.
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Hypothesis H1. HF patient costs at U of U Health will begin to decline post IPU
implementation.
Total Heart Failure Cost Per Patient (All HF, VAD, and Transplant)
There was a 21% initial increase in costs post IPU implementation followed by a
1% increase in cost slope between the pre and post intervention time periods, which is
not statistically significant with a p-value of .712. This similar pattern in cost trend
occurred in both technical and professional fees with p-values of .706 and .759
respectively, as illustrated in Graphs 1 – 3.
Graph 1. HF Cost Per Patient (All) Normalized and Adjusted Trends
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Graph 2. HF Technical Cost Per Patient (All) Normalized and Adjusted Trends

Graph 3. HF Professional Cost Per Patient (All) Normalized and Adjusted Trends
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Heart Failure Costs – HF Patients Only
Costs for HF patients only, excluding VADs and Transplants, increased 23% post
implementation of the IPU and declined in slope by 3% between the post time periods.
The change in slope is not statistically significant for these HF patients with a p-value of
.096 (Graph 4).
Graph 4. HF Cost Normalized and Adjusted Trends

Heart Failure Cost – Surgical and Nonsurgical
There are statistically significant changes when the population cost data is
segmented by surgical and non-surgical patients. Heart failure cost for surgical patients
show an initial decline (3%) in costs post implementation of the IPU followed by a
statistically significant downward trend (p-value .041) of 6% in slope between the pre
and post intervention periods. This trend is especially strong in the post intervention time
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period with a p-value of .005. Nonsurgical HF costs are also on the decline with a
statistically significant reduction in the post intervention time period (p-value .025) as
illustrated in Graphs 5 and 6.
Graph 5. HF Cost – Surgical Normalized and Adjusted Trends
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Graph 6. HF Cost – Nonsurgical Normalized and Adjusted Trends
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HF Ventricular Assisted Device (VAD) Cost
HF VAD costs experienced an initial drop of 23% post implementation of the HF
IPU, and a slight increase of 4% in slope between the pre and post intervention period.
The slope change was not statistically significant with a p-value of .097 (Graph 7).
Graph 7. HF VAD Cost Normalized and Adjusted Trends

HF Transplant Cost
After normalizing and adjusting for outliers, there were not enough HF Transplant
patients to measure statistical significance.
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Hypothesis H2. HF admissions, ED visits, readmissions, and observed/expected
LOS will decline post IPU implementation.
HF Admissions
Admissions per 1000 patients increased in the post period by 15.7 with a slope
increase of .29 between the pre and post periods, reflecting little change in admission
patterns. Change in admissions were not statistically significant with a p-value of .930
(Graph 8).
Graph 8. HF Admissions Per 1000 Patients Adjusted Trends
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HF Emergency Department Visits
Emergency Department (ED) visits per 1000 patients have declined post
implementation of the IPU by -8.61 with a slope decline of -.1.75
between the pre and post periods. This trend is not statistically significant with a p-value
of .259 (Graph 9). However, the decline in visits is remarkable and appears to have been
sustainable over the post period.
Graph 9. HF ED Visits Per 1000 Patients Adjusted Trends
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HF Readmissions
Heart failure all cause readmission rates dropped .005 post IPU implementation
with a slope change of .008 between the pre and post periods. Trends are not statistically
significant with a p-value of .383. In addition, there appears to be less variability in
readmission patterns post implementation of the IPU model (Graph 10).
Graph 10. HF Readmission Rate Adjusted Trends
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HF Mean Length of Stay
HF mean length of stay increased post implementation .69 with a slope decline of
-.12 between pre and post periods. This decline is not statistically significant with a pvalue of .515 (Graph 11).
Graph 11. HF Mean Length of Stay
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CHAPTER V
DISCUSSION

Discussion of Results
Implementation of the HF IPU model in and of itself did not have a statistically
significant impact on total HF costs; however, when costs were broken down into HF
Surgical and Non-surgical patients, there were statistically significant declines in costs.
Other cost indicators such as mean LOS, ED visits, technical, and professional cost trends
were also on the decline, yet not statistically significant.
In some cases, however, the declining trends may be financially or clinically
significant. It is important to note the difference between statistical significance and
clinical significance. The p-values represent the probability that the results were due to
some level of chance. It does not measure the treatment effect or significance of the
change. One measure may be more statistically significant than another; however, the
magnitude of change may be greater or less. ITS graphs allow the researchers to observe
the level of change while also testing for statistical significance in trying to determine if
the results are robust enough to be clinically significant (P values, 2016).
This research had similar outcomes to another study published in JAMA
measuring the association of this same value driven outcomes tool with cost reduction
and improvement in health outcomes. The researchers concluded that identifying
variability in costs and quality outcomes and sharing this data with physicians may help
in improving care (Lee, et al., 2016). While both studies are unique to University of Utah
Health, other costing methodologies that incorporate patient level cost data could be used
to track change over time. The ability to identify and monitor actual health care delivery
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costs is a critical component of improving the value of health care (Lee et al., 2016;
Porter & Lee, 2013).
The Integrated Time Series (ITS) regression analysis and design approach is
perhaps the most generalizable aspect of this research. This methodology can be
extended to incorporate other interventions; and more importantly, be applied to other
quality improvement initiatives in measuring the impact of an intervention on cost and/or
quality outcomes. ITS is a simple, persuasive tool used to evaluate the impact of a
change or intervention on an outcome for a specific population of individuals. It is
especially useful when a randomized control study is not possible, or perhaps even
unethical (Penfold & Zhang, 2013).
If we do see a change in cost, what is driving it? Do you need an IPU model to
improve patient costs and outcomes? The study does not answer these questions directly;
however, in order to study a population, practice patterns, or cost and quality data, there
needs to be a physician-led team that is motivated to improve patient value, and
accountable for performance defined by measurable outcomes. Identifying variability in
care often requires external review by value engineers or process improvement experts.
The tenets of Porter and Lee’s IPU model as well as the other integrated care approaches
reinforce these principles (Mitchell, et al., 2015; McKay and Wieck, 2014; Bogaev, 2010;
Porter & Teisberg, 2007).
In subsequent dialogue with the HF IPU leadership, participants noted challenges
such as the ability to obtain reliable data, variability in patient mix, identification of
meaningful process improvements, clinical team coordination, episode of care verses
longitudinal care coordination, budgetary and other more cultural issues. As one leader
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stated, “Committee driven implementation is slow. There is much work to be done
translating ideas from the board room to the bedside.” Also important were discussions
about how best to build the academic and research components into the IPU model.
(James Fang, personal interview, 2017).
Some of the advantages cited by the HF IPU leadership team included improved
organizational alignment and service integration, creation of more formal goals, focus on
patient-centered care and clinical care pathways, and development of a framework for
patient reported outcomes measures to support future research. Future IPU opportunities
were noted, such as extending the IPU to the entire service line, creating more actionable
data, developing and monitoring “perfect care” indices for patient procedures,
implementing heart failure discharge interventions to further reduce readmissions, and
improving the heart failure care pathway from primary care through more home-based
care. Lastly, suggestions for change within the IPU model encompassed the need for a
dedicated budget and support staff, broader operational representation with a population
health approach, and more efficient decision making power (U of U Health HF IPU
Leadership, personal interviews, 2017).
Conclusions
There were several lessons learned or additional conclusions drawn from this
study, including the following:
•

Segmenting the analysis by patient type is important in understanding true cost
variation. By aggregating all HF patient costs, statistically significant differences
are masked by the data.
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Extending the time period of both the post periods, will increase the power of the
study results (Bernal, Cummins, & Gasparrini, 2016). The initial research plan
was to use two years one year post; however, the integrity of the FY14 costing
data was questionable.

•

Moving the post period out six months or more may impact results, since with any
new program implementation there is often a learning curve or ramp up in the
beginning before real change can occur.

•

Focusing on changes in practice that reduce technical costs, such as supplies,
operating room time and diagnostic tests will have the greatest impact on costs.
Total HF cost and total HF technical cost trends and slope change are almost
identical. Total HF professional costs did not appear to have a significant impact
on total cost as illustrated in the differences observed in the pre intervention
period.

•

Understanding the Hawthorne effect whereby providers are changing their
behavior based on new knowledge, different incentives, or just the fact that they
are being studied is important given that there were no significant changes in
practice or providers noted over the post periods (Shuttleworth, 2016).

•

Rewarding the same fee for service driven care even in an IPU model does not
necessarily incentivize population health approaches to care; rather it supports
continuous improvement in both volumes and quality.

•

Measuring episode of care costs and even other related costs within the same
health care delivery system is a start; however, we need access to patient data
sources from other facilities and over different time periods to understand true
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population health costs. Currently, this level of reliable data sharing is
nonexistent. Therefore, most cost studies are from the perspective of established
payer databases and not based on actual patient care delivery costs.
Future Study
There are plenty of opportunities for future cost studies both within University of
Utah Health and beyond. Internally, researchers may choose to extend the study time
period to test whether the change is truly linear and sustainable. Layering in other
interventions that might further impact cost and patient outcomes would strengthen the
power of the study. Comparing this population of HF patients in the IPU to another
similar cohort outside of the IPU would also enhance the study’s validity.
Combining quality outcomes research, such as patient mortality and other HF
related patient outcome indicators, with this type of cost analysis would add to the
understanding of value-based outcomes research and potential study methodologies.
Incorporating patient reported outcomes and examining the correlation between
these reported outcomes and cost would lend to the body of comparative effectiveness
research, and bring a unique cost perspective to traditionally more clinically oriented
outcomes studies.
In addition, the costing methodology using ITS regression analysis can be refined
and applied to other services to track interventions across disease types, and serve as a
model for standardizing the impact of costs across the organization. Studying the
financial integration and alignment of incentives within the IPU model and its operational
structure may also shed additional light on motivations behind changes in cost.

A QUANTITATIVE REVIEW OF COSTS

57

Externally, the research could be expanded to include a broader HF population
through collaborations with other cardiologists and primary care physicians. Careful
attention would need to be given to defining the population, and obtaining a consistent
data set for comparison.
Analyzing payer costs for those HF patients treated at University of Utah Health
versus other health systems utilizing data from an all payer data base or Medicare may be
another useful comparison. It would be interesting to see if payer costs correlate with
actual patient care delivery costs.
Summary
Knowing the cost of delivering patient care is a mandatory first step as health care
leaders are tasked with reducing the cost of US health care. The Center for Medicare and
Medicaid Services (CMS) has targeted heart failure patients and their related health care
expenses as a potential opportunity to reduce national health care costs. In 2009, the
estimated cost of treating heart failure patients in the US was greater than $30 billion, and
costs are expected to more-than-double in 15 years.
Conditions have never been more favorable for structural redesign and
examination of innovative care delivery models focused on improving the value of health
care. Integral to improving value is measuring and understanding actual costs at the
individual patient level. The IPU is a patient-centered organizational framework whose
principles support population health for specific conditions and value-driven care. To
date, there are very few health systems that can measure actual patient care delivery costs
that include both hospital and professional expenses for inpatient and outpatient care. U
of U Health has developed a proprietary costing model that gives them the ability to
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measure both costs and outcomes at the patient, provider, program, or in this research
case, IPU level.
The design of the study is a quantitative analysis of a program evaluation using
archival data from U of U Health. An interrupted time series (ITS) study design
methodology is used to evaluate whether there has been an immediate effect on HF
patient costs post implementation of the HF IPU. The ITS is one of the strongest, quasiexperimental approaches for evaluating the effects of population level health
interventions that are implemented at a point in time. The ITS pre/posttest design is often
used to test statistical change in an outcome rate in the time periods before and after
implementation of a program designed to change the outcome (Wagner, Soumerai,
Zhang, & Ross-Degan, 2002; Bernal, Cummins, & Gasparrini, 2016).
The ITS pre/post analyses show an overall declining trend in total HF costs, total
HF technical costs, total HF professional costs, HF costs (total, surgical and nonsurgical), admissions, ED visits, and mean LOS. While VAD costs dropped initially, it
began to increase in the post intervention period. HF readmissions remained flat across
the pre and post periods. Statistically significant and declining trends were observed in
HF surgical, and non-surgical cost trends. While some trends were not statistically
significant, they may be deemed financially or clinically significant and worth further
study.
There are plenty of opportunities for additional research. The results of this
quantitative analysis of a HF IPU program adds to the body of research knowledge on the
design of IPUs and their subsequent impact on costs, as well as informs health care
leaders of the challenges and lessons learned in managing a specific population, aligning
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incentives and costs, and developing analytical tools that support a more integrated,
longitudinal treatment approach to improving patients’ health.
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APPENDIX A

Diagnosis Codes Used to Define HF Patient Population
Diagnosis Code
428.9
745.2
V43.21
428.22
402.91
398.91
428.41
I50.31
Z95.3
O90.3
I40.0
Z48.22
Z48.23
D86.84
Z48.290
I50.40
T81.11XA
I25.750
276.69
428.42
746.7
277.39
422.91
404.13
E87.70
I51.81
I11.0
Z95.4
E85.4
Z48.21
B25.9
B25.0
T86.22
E85.2
I40.1
J18.2

Diagnosis Code Description
UNSPECIFIED HEART FAILURE
TETRALOGY OF FALLOT
ORGAN/TISSUE REPL OTH MEANS HRT ASSIST DEVICE
CHRONIC SYSTOLIC HEART FAILURE
HYPERTENSIVE HEART DISEASE UNSPEC W/HEART FAIL
RHEUMATIC HEART FAILURE
ACUTE COMBINED SYSTOLIC&DIASTOLIC HEART FAILURE
ACUTE DIASTOLIC CONGESTIVE HEART FAILURE
PRESENCE OF XENOGENIC HEART VALVE
PERIPARTUM CARDIOMYOPATHY
INFECTIVE MYOCARDITIS
ENCOUNTER AFTERCARE FOLLOWING KIDNEY TRANSPLANT
ENCOUNTER AFTERCARE FOLLOWING LIVER TRANSPLANT
SARCOID PYELONEPHRITIS
ENCOUNTER AFTERCARE FLW BONE MARROW TRANSPLANT
UNSPECIFIED COMBINED SYSTOLIC & DIASTOLIC CHF
POSTPROCEDURAL CARDIOGENIC SHOCK INITIAL ENC
ATHEROSCLER NATV COR ART TPLNT HRT W/UNSTABLE AP
OTHER FLUID OVERLOAD
CHRONIC COMB SYSTOLIC&DIASTOLIC HEART FAILURE
HYPOPLASTIC LEFT HEART SYNDROME
OTHER AMYLOIDOSIS
IDIOPATHIC MYOCARDITIS
HTN HEART & CKD BEN W/HF & CKD STAGE V/ESRD
FLUID OVERLOAD UNSPECIFIED
TAKOTSUBO SYNDROME
HYPERTENSIVE HEART DISEASE WITH HEART FAILURE
PRESENCE OF OTHER HEART-VALVE REPLACEMENT
ORGAN-LIMITED AMYLOIDOSIS
ENCOUNTER AFTERCARE FOLLOWING HEART TRANSPLANT
CYTOMEGALOVIRAL DISEASE UNSPECIFIED
CYTOMEGALOVIRAL PNEUMONITIS
HEART TRANSPLANT FAILURE
HEREDOFAMILIAL AMYLOIDOSIS UNSPECIFIED
ISOLATED MYOCARDITIS
HYPOSTATIC PNEUMONIA UNSPECIFIED ORGANISM
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Z48.280
T86.31
423.2
V42.1
V42.1
425.11
428.32
996.83
428.1
404.11
R57.0
Q23.4
I42.1
I50.30
D86.81
I40.9
B25.1
V58.44
514
425.5
428.21
429.83
428.43
B25.8
I50.22
J81.1
I13.0
I51.7
I42.0
I09.81
Z95.811
I42.8
Z48.288
I42.7
T86.20
I42.4
B25.2

ENCOUNTER AFTERCARE FOLLOW HEART-LUNG
TRANSPLANT
HEART-LUNG TRANSPLANT REJECTION
CONSTRICTIVE PERICARDITIS
CAR PSGR INJ COLL 2/3-WHL MOTOR VEH NONTRAF ACC
HEART REPLACED BY TRANSPLANT
HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY
CHRONIC DIASTOLIC HEART FAILURE
COMPLICATIONS OF TRANSPLANTED HEART
LEFT HEART FAILURE
HTN HRT & CKD BEN W/HF & W/CKD STAGE I-IV/UNS
CARDIOGENIC SHOCK
HYPOPLASTIC LEFT HEART SYNDROME
OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
UNSPECIFIED DIASTOLIC CONGESTIVE HEART FAILURE
SARCOID MENINGITIS
ACUTE MYOCARDITIS UNSPECIFIED
CYTOMEGALOVIRAL HEPATITS
AFTERCARE FOLLOWING ORGAN TRANSPLANT
PULMONARY CONGESTION AND HYPOSTASIS
ALCOHOLIC CARDIOMYOPATHY
ACUTE SYSTOLIC HEART FAILURE
TAKOTSUBO SYNDROME
ACUTE CHRONIC COMB SYSTOLIC&DIASTOLIC HEART FAIL
OTHER CYTOMEGALOVIRAL DISEASES
CHRONIC SYSTOLIC CONGESTIVE HEART FAILURE
CHRONIC PULMONARY EDEMA
HTN HEART & CKD W/HF & CKD STAGE 1-4 OR UNS CKD
CARDIOMEGALY
DILATED CARDIOMYOPATHY
RHEUMATIC HEART FAILURE
PRESENCE OF HEART ASSIST DEVICE
OTHER CARDIOMYOPATHIES
ENCOUNTER AFTERCARE FLW MULTI ORGAN TRANSPLANT
CARDIOMYOPATHY DUE TO DRUG AND EXTERNAL AGENT
UNSPECIFIED COMPLICATION OF HEART TRANSPLANT
ENDOCARDIAL FIBROELASTOSIS
CYTOMEGALOVIRAL PANCREATITIS

D86.3
E85.1
425.4

SARCOIDOSIS OF SKIN
NEUROPATHIC HEREDOFAMILIAL AMYLOIDOSIS
OTHER PRIMARY CARDIOMYOPATHIES
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V42.2
789.59
V43.21
428.31
I50.20
I50.33
D86.0
I13.2
I50.43
D86.89
I42.2
D86.85
I31.1
T86.23
T86.39
429.3
425.3
414.06
R18.8
I50.9
D86.9
I50.1
I50.23
I50.32
Q20.3
T86.290
Z48.298
D86.1
425.18
V87.46
428.23
785.51
674.54
428
I50.21
E87.79
I50.41
Q21.3
Z94.1
E85.3
D86.83
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HEART VALVE REPLACED BY TRANSPLANT
OTHER ASCITES
PERSON OUTSIDE CAR INJURED COLL SUV NONTRAF ACC
ACUTE DIASTOLIC HEART FAILURE
UNSPECIFIED SYSTOLIC CONGESTIVE HEART FAILURE
ACUTE ON CHRON DIASTOLIC CONGESTIV HEART FAILURE
SARCOIDOSIS OF LUNG
HTN HEART & CKD W/HF W/STAGE 5 CKD OR ESRD
ACUTE ON CHRONIC COMB SYSTOLIC & DIASTOLIC CHF
SARCOIDOSIS OF OTHER SITES
OTHER HYPERTROPHIC CARDIOMYOPATHY
SARCOID MYOCARDITIS
CHRONIC CONSTRICTIVE PERICARDITIS
HEART TRANSPLANT INFECTION
OTHER COMPLICATIONS OF HEART-LUNG TRANSPLANT
CARDIOMEGALY
ENDOCARDIAL FIBROELASTOSIS
COR ATHEROSLERO COR ART TRANSPLANTED HEART
OTHER ASCITES
HEART FAILURE UNSPECIFIED
SARCOIDOSIS UNSPECIFIED
LEFT VENTRICULAR FAILURE
ACUTE CHRON SYSTOLIC HEART FAILURE
CHRONIC DIASTOLIC CONGESTIVE HEART FAILURE
DISCORDANT VENTRICULOARTERIAL CONNECTION
CARDIAC ALLOGRAFT VASCULOPATHY
ENCOUNTER AFTERCARE FOLLOW OTH ORGAN TRANSPLANT
SARCOIDOSIS OF LYMPH NODES
OTHER HYPERTROPHIC CARDIOMYOPATHY
PERSONAL HISTORY OF IMMUNOSUPPRESSION THERAPY
ACUTE ON CHRONIC SYSTOLIC HEART FAILURE
CARDIOGENIC SHOCK
PERIPARTUM CARDIOMYOPATHY POSTPARTUM COND/COMP
HEART FAILURE
ACUTE SYSTOLIC CONGESTIVE HEART FAILURE
OTHER FLUID OVERLOAD
ACUTE COMBINED SYSTOLIC AND DIASTOLIC CHF
TETRALOGY OF FALLOT
HEART TRANSPLANT STATUS
SECONDARY SYSTEMIC AMYLOIDOSIS
SARCOID IRIDOCYCLITIS
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T86.21
T86.298
Z94.3
D86.87
I25.759
425.9
135
V42.2
428.33
998.01
I42.9
I50.42
I42.6
I51.4
I25.811
Z92.25
E85.9
E85.8
I42.5
D86.86
Z48.24
D86.2
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HEART TRANSPLANT REJECTION
OTHER COMPLICATIONS OF HEART TRANSPLANT
HEART AND LUNGS TRANSPLANT STATUS
SARCOID MYOSITIS
ATHEROSCLEROSIS NATV COR ART TPLNT HRT W/UNS AP
UNSPECIFIED SECONDARY CARDIOMYOPATHY
SARCOIDOSIS
PERS OUTSIDE CAR INJ COLL 2/3-WHL MV NONTRAF ACC
ACUTE ON CHRONIC DIASTOLIC HEART FAILURE
POSTOPERATIVE SHOCK CARDIOGENIC
CARDIOMYOPATHY UNSPECIFIED
CHRONIC COMBINED SYSTOLIC AND DIASTOLIC CHF
ALCOHOLIC CARDIOMYOPATHY
MYOCARDITIS UNSPECIFIED
ATHEROSCLEROSIS NATIVE COR ART TPLNT HRT W/O AP
PERSONAL HISTORY OF IMMUNOSUPRESSION THERAPY
AMYLOIDOSIS UNSPECIFIED
OTHER AMYLOIDOSIS
OTHER RESTRICTIVE CARDIOMYOPATHY
SARCOID ARTHROPATHY
ENCOUNTER AFTERCARE FOLLOWING LUNG TRANSPLANT
SARCOIDOSIS OF LUNG W/SARCOIDOSIS OF LYMPH NODES

(Source: U of U Health, EDW, October 2016)
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APPENDIX B

HF Patient Population Independent Data Codes and Queries (July 1, 2013 – June
30, 2016)
Visit Codes:
,V. VISIT_NO
,PRM.VISIT_NO AS PRIMARY_VISIT_NO
,REPROV.PERFORMING_CONTACT_DWID
,P.PAT_ID AS PATIENT_MRN
,P. BIRTH_DATE
,LOC.UNIT_TYPE_CODE
,PMATTD.PROV_EXTERNAL_NAME
,PMATTD.DIVISION
,GNDR.CODE AS GENDER
,GNDR.D_GENDER_DESC AS GENDER_DESC
,RCE.CODE AS RACE
,RCE.D_RACE_DESC AS RACE_DESC
,ETHNC.CODE AS ETHNICITY
,ETHNC.D_ETHNICITY_DESC AS ETHNICITY_DESC
,PC.CODE AS PAT_CLASS
,PC.D_PAT_CLASS_DESC AS PAT_CLASS_DESC
,P.ZIP
,V.ADM_DATE
,V.DSCH_DATE
,DBP.MIN_ADM_DATE
,VDC.CCI_SCORE AS CHARLSON_COMORBIDITY_INDEX
Diagnosis Codes:
,DX1.CODE AS DX1_CODE
,DX1.D_ICD_DX_DESC AS DX1_CODE_DESC
,DX2.CODE AS DX2_CODE
,DX2.D_ICD_DX_DESC AS DX2_CODE_DESC
,DX3.CODE AS DX3_CODE
,DX3.D_ICD_DX_DESC AS DX3_CODE_DESC
,DX4.CODE AS DX4_CODE
,DX4.D_ICD_DX_DESC AS DX4_CODE_DESC
,DX5.CODE AS DX5_CODE
,DX5.D_ICD_DX_DESC AS DX5_CODE_DESC
,DX6.CODE AS DX6_CODE
,DX6.D_ICD_DX_DESC AS DX6_CODE_DESC
,DX7.CODE AS DX7_CODE
,DX7.D_ICD_DX_DESC AS DX7_CODE_DESC
,DX8.CODE AS DX8_CODE
,DX8.D_ICD_DX_DESC AS DX8_CODE_DESC
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,DX9.CODE AS DX9_CODE
,DX9.D_ICD_DX_DESC AS DX9_CODE_DESC
,DX10.CODE AS DX10_CODE
,DX10.D_ICD_DX_DESC AS DX10_CODE_DESC
ICD Procedure Codes:
,PX1.CODE AS PX1_CODE
,PX1.D_ICD_PX_DESC AS PX1_CODE_DESC
,PM1.PROV_EXTERNAL_NAME AS PX1_PROVIDER
,PX2.CODE AS PX2_CODE
,PX2.D_ICD_PX_DESC AS PX2_CODE_DESC
,PM2.PROV_EXTERNAL_NAME AS PX2_PROVIDER
,PX3.CODE AS PX3_CODE
,PX3.D_ICD_PX_DESC AS PX3_CODE_DESC
,PM3.PROV_EXTERNAL_NAME AS PX3_PROVIDER
,PX4.CODE AS PX4_CODE
,PX4.D_ICD_PX_DESC AS PX4_CODE_DESC
,PM4.PROV_EXTERNAL_NAME AS PX4_PROVIDER
,PX5.CODE AS PX5_CODE
,PX5.D_ICD_PX_DESC AS PX5_CODE_DESC
,PM5.PROV_EXTERNAL_NAME AS PX5_PROVIDER
,PX6.CODE AS PX6_CODE
,PX6.D_ICD_PX_DESC AS PX6_CODE_DESC
,PM6.PROV_EXTERNAL_NAME AS PX6_PROVIDER
,PX7.CODE AS PX7_CODE
,PX7.D_ICD_PX_DESC AS PX7_CODE_DESC
,PM7.PROV_EXTERNAL_NAME AS PX7_PROVIDER
,PX8.CODE AS PX8_CODE
,PX8.D_ICD_PX_DESC AS PX8_CODE_DESC
,PM8.PROV_EXTERNAL_NAME AS PX8_PROVIDER
,PX9.CODE AS PX9_CODE
,PX9.D_ICD_PX_DESC AS PX9_CODE_DESC
,PM9.PROV_EXTERNAL_NAME AS PX9_PROVIDER
,PX10.CODE AS PX10_CODE
,PX10.D_ICD_PX_DESC AS PX10_CODE_DESC
,PM10.PROV_EXTERNAL_NAME AS PX10_PROVIDER
CPT Codes:
,CPT1.CODE AS CPT1_CODE
,CPT1.D_CPT_HCPC_DESC AS CPT1_CODE_DESC
,CPT2.CODE AS CPT2_CODE
,CPT2.D_CPT_HCPC_DESC AS
,CPT3.CODE AS CPT3_CODE
,CPT3.D_CPT_HCPC_DESC AS CPT3_CODE_DESC
,CPT04.CODE AS CPT4_CODE
,CPT04.D_CPT_HCPC_DESC AS CPT4_CODE_DESC
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,CPT5.CODE AS CPT5_CODE
,CPT5.D_CPT_HCPC_DESC AS CPT5_CODE_DESC
,CPT6.CODE AS CPT6_CODE
,CPT6.D_CPT_HCPC_DESC AS CPT6_CODE_DESC
,CPT7.CODE AS CPT7_CODE
,CPT7.D_CPT_HCPC_DESC AS CPT7_CODE_DESC
,CPT8.CODE AS CPT8_CODE
,CPT8.D_CPT_HCPC_DESC AS CPT8_CODE_DESC
,CPT9.CODE AS CPT9_CODE
,CPT9.D_CPT_HCPC_DESC AS CPT9_CODE_DESC
,CPT10.CODE AS CPT10_CODE
,CPT10.D_CPT_HCPC_DESC AS CPT10_CODE_DESC
Imaging, Supplies, Pharmacy, Facility, and Professional Cost Queries:
,ROUND(CLC.IMAGING_DIR_COST_AMT + SUPPLY_DIR_COST_AMT +
PHARMACY_DIR_COST_AMT +
LAB_DIR_COST_AMT + OTHER_SRVC_DIR_COST_AMT
+ FACILITY_UTIL_DIR_AMT +
PROF_DEPT_STAFF_COST_AMT + PROF_PROVIDER_COST_AMT +
PROF_NON_PERSONNEL_COST_AMT +
IMPLANT_DIR_COST_AMT + LAB_MNGMNT_DIR_COST_AMT +
INSTITUTIONAL_DIR_COST_AMT, 2) AS TOTAL_DIR_COST
(Source: U of U Health EDW, October 2016)
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APPENDIX C

All Syntax Data Definitions and Queries using Stata 14.0
***All patients
*total cost
tsset time
itsa its_total_cost_norm pc_male pc_white mean_cci mean_age, single trperiod(0) lag(1)
figure posttrend
actest, lag(5)
ge adjusted=_s_its_total_cost_norm_pred
drop _t _x0 _x_t0 _s_its_total_cost_norm_pred

itsa its_total_cost_norm , single trperiod(0) lag(1) figure posttrend
actest, lag(5)
ge unadjusted=_s_its_total_cost_norm_pred
drop _t _x0 _x_t0 _s_its_total_cost_norm_pred

twoway (scatter its_total_cost_norm time) (line adjusted time, lcolor(blue)) (line
unadjusted time, lcolor(red) lpattern(shortdash) ), yline(0.65, lcolor(green)) ///
ytitle(Normalized Total Cost Per PT) xtitle(Month)
drop adjusted unadjusted

*total tech cost
tsset time
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itsa its_tech_cost_norm pc_male pc_white mean_cci mean_age, single trperiod(0) lag(1)
figure posttrend
actest, lag(5)
ge adjusted=_s_its_tech_cost_norm_pred
drop _t _x0 _x_t0 _s_its_tech_cost_norm_pred

itsa its_tech_cost_norm , single trperiod(0) lag(1) figure posttrend
actest, lag(5)
ge unadjusted=_s_its_tech_cost_norm_pred
drop _t _x0 _x_t0 _s_its_tech_cost_norm_pred

twoway (scatter its_tech_cost_norm time) (line adjusted time, lcolor(blue)) (line
unadjusted time, lcolor(red) lpattern(shortdash) ), yline(0.64, lcolor(green)) ///
ytitle(Normalized Tech Cost Per PT) xtitle(Month)
drop adjusted unadjusted

*total prof cost
tsset time
itsa its_prof_cost_norm pc_male pc_white mean_cci mean_age, single trperiod(0) lag(1)
figure posttrend
actest, lag(5)
ge adjusted=_s_its_prof_cost_norm_pred
drop _t _x0 _x_t0 _s_its_prof_cost_norm_pred
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itsa its_prof_cost_norm , single trperiod(0) lag(1) figure posttrend
actest, lag(5)
ge unadjusted=_s_its_prof_cost_norm_pred
drop _t _x0 _x_t0 _s_its_prof_cost_norm_pred

twoway (scatter its_prof_cost_norm time) (line adjusted time, lcolor(blue)) (line
unadjusted time, lcolor(red) lpattern(shortdash) ), yline(0.68, lcolor(green)) ///
ytitle(Normalized professional Cost Per PT) xtitle(Month)
drop adjusted unadjusted

*ED per 1000
tsset time
itsa ed_per1000 pc_male pc_white mean_cci mean_age, single trperiod(0) lag(1) figure
posttrend
actest, lag(5)
ge adjusted= _s_ed_per1000_pred
drop _t _x0 _x_t0 _s_ed_per1000_pred

itsa ed_per1000, single trperiod(0) lag(1) figure posttrend
actest, lag(5)
ge unadjusted= _s_ed_per1000_pred
drop _t _x0 _x_t0 _s_ed_per1000_pred
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twoway (scatter ed_per1000 time) (line adjusted time, lcolor(blue)) (line unadjusted time,
lcolor(red) lpattern(shortdash) ), yline(20, lcolor(green)) ///
ytitle(ED Visits Per 1000) xtitle(Month)
drop adjusted unadjusted

*admit per 1000
tsset time
itsa admit_per1000 pc_male pc_white mean_cci mean_age, single trperiod(0) lag(1)
figure posttrend
actest, lag(5)
ge adjusted=_s_admit_per1000_pred
drop _t _x0 _x_t0 _s_admit_per1000_pred

itsa admit_per1000, single trperiod(0) lag(1) figure posttrend
actest, lag(5)
ge unadjusted=_s_admit_per1000_pred
drop _t _x0 _x_t0 _s_admit_per1000_pred

twoway (scatter admit_per1000 time) (line adjusted time, lcolor(blue)) (line unadjusted
time, lcolor(red) lpattern(shortdash) ), yline(152, lcolor(green)) ///
ytitle(Inpatient Admissions Per 1000) xtitle(Month)
drop adjusted unadjusted
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*readmit per 1000
tsset time
itsa readmit_rate pc_male pc_white mean_cci mean_age, single trperiod(0) lag(1) figure
posttrend
actest, lag(5)
ge adjusted=_s_readmit_rate_pred
drop _t _x0 _x_t0 _s_readmit_rate_pred

itsa readmit_rate, single trperiod(0) lag(1) figure posttrend
actest, lag(5)
ge unadjusted=_s_readmit_rate_pred
drop _t _x0 _x_t0 _s_readmit_rate_pred

twoway (scatter readmit_rate time) (line adjusted time, lcolor(blue)) (line unadjusted
time, lcolor(red) lpattern(shortdash) ), yline(0.19, lcolor(green)) ///
ytitle(Readmission Rate) xtitle(Month)
drop adjusted unadjusted

*average LOS
tsset time
itsa mean_los pc_male pc_white mean_cci mean_age, single trperiod(0) lag(1) figure
posttrend
actest, lag(5)
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ge adjusted=_s_mean_los_pred
drop _t _x0 _x_t0 _s_mean_los_pred

itsa mean_los, single trperiod(0) lag(1) figure posttrend
actest, lag(5)
ge unadjusted=_s_mean_los_pred
drop _t _x0 _x_t0 _s_mean_los_pred

twoway (scatter mean_los time) (line adjusted time, lcolor(blue)) (line unadjusted time,
lcolor(red) lpattern(shortdash) ), yline(8.4, lcolor(green)) ///
ytitle(Average LOS) xtitle(Month)
drop adjusted unadjusted

***subsets*****
*VAD
tsset time
itsa cost_vad_norm pc_male pc_white mean_cci mean_age, single trperiod(0) lag(1)
figure posttrend
actest, lag(5)
ge adjusted=_s_cost_vad_norm_pred
drop _t _x0 _x_t0 _s_cost_vad_norm_pred

itsa cost_vad_norm, single trperiod(0) lag(1) figure posttrend
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actest, lag(5)
ge unadjusted=_s_cost_vad_norm_pred
drop _t _x0 _x_t0 _s_cost_vad_norm_pred

twoway (scatter cost_vad_norm time) (line adjusted time, lcolor(blue)) (line unadjusted
time, lcolor(red) lpattern(shortdash) ), yline(0.49, lcolor(green)) ///
ytitle(Normalized Total Cost Per PT) xtitle(Month)
drop adjusted unadjusted

*HF
tsset time
itsa cost_hf_norm pc_male pc_white mean_cci mean_age, single trperiod(0) lag(1)
figure posttrend
actest, lag(5)
ge adjusted=_s_cost_hf_norm_pred
drop _t _x0 _x_t0 _s_cost_hf_norm_pred

itsa cost_hf_norm, single trperiod(0) lag(1) figure posttrend
actest, lag(5)
ge unadjusted=_s_cost_hf_norm_pred
drop _t _x0 _x_t0 _s_cost_hf_norm_pred
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twoway (scatter cost_hf_norm time) (line adjusted time, lcolor(blue)) (line unadjusted
time, lcolor(red) lpattern(shortdash) ), yline(0.52, lcolor(green)) ///
ytitle(Normalized Total Cost Per PT) xtitle(Month)
drop adjusted unadjusted

*HF-surgical
tsset time
itsa cost_surgical_norm pc_male pc_white mean_cci mean_age, single trperiod(0) lag(1)
figure posttrend
actest, lag(5)
ge adjusted=_s_cost_surgical_norm_pred
drop _t _x0 _x_t0 _s_cost_surgical_norm_pred

itsa cost_surgical_norm, single trperiod(0) lag(1) figure posttrend
actest, lag(5)
ge unadjusted=_s_cost_surgical_norm_pred
drop _t _x0 _x_t0 _s_cost_surgical_norm_pred

twoway (scatter cost_surgical_norm time) (line adjusted time, lcolor(blue)) (line
unadjusted time, lcolor(red) lpattern(shortdash) ), yline(0.459, lcolor(green)) ///
ytitle(Normalized Total Cost Per PT) xtitle(Month)
drop adjusted unadjusted
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*HF-nonsurgical
tsset time
itsa cost_nonsurgical_norm pc_male pc_white mean_cci mean_age, single trperiod(0)
lag(1) figure posttrend
actest, lag(5)
ge adjusted=_s_cost_nonsurgical_norm_pred
drop _t _x0 _x_t0 _s_cost_nonsurgical_norm_pred

itsa cost_nonsurgical_norm, single trperiod(0) lag(1) figure posttrend
actest, lag(5)
ge unadjusted=_s_cost_nonsurgical_norm_pred
drop _t _x0 _x_t0 _s_cost_nonsurgical_norm_pred

twoway (scatter cost_nonsurgical_norm time) (line adjusted time, lcolor(blue)) (line
unadjusted time, lcolor(red) lpattern(shortdash) ), yline(0.4937, lcolor(green)) ///
ytitle(Normalized Total Cost Per PT) xtitle(Month)
drop adjusted unadjusted
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APPENDIX D

ITS Regression Analysis Data Set
Summary Table 1
Time
Number of
Total
in Months
Patients
-12
580
-11
608
-10
612
-9
676
-8
597
-7
624
-6
624
-5
694
-4
724
-3
711
-2
699
-1
711
0
748
1
721
2
782
3
630
4
610
5
614
6
576
7
618
8
666
9
620
10
663
11
639
15747

Total
Visits
1340
1390
1382
1652
1317
1510
1506
1616
1822
1649
1679
1751
1820
1706
1887
1408
1326
1409
1219
1341
1585
1409
1391
1386
36501

Average
Age
63.00
63.00
63.00
64.00
63.00
64.00
64.00
63.00
63.00
63.00
64.00
64.00
64.00
64.00
63.00
63.00
62.00
62.00
61.00
62.00
62.00
61.00
61.00
62.00
62.83

Average
%
Male
67.24
66.61
65.20
63.46
64.99
63.94
64.74
67.15
64.09
64.56
64.66
66.81
64.30
65.05
66.75
64.76
67.54
68.57
67.01
66.83
67.57
69.03
67.12
70.74
66.20

%
White
86.72
86.02
86.27
87.43
85.59
87.02
86.70
87.03
84.94
86.08
86.98
87.48
86.23
85.71
86.57
85.40
83.61
83.88
83.51
84.63
84.83
85.81
83.56
83.41
85.64

CCI
5.10
5.14
4.95
4.99
5.28
5.03
5.21
4.98
5.15
5.10
5.17
5.17
5.17
5.17
4.98
5.15
5.10
5.38
5.21
5.17
5.14
5.10
5.12
5.15
5.13
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ITS Regression Analysis Data Set

Summary Table 2
Norm
Time alized
Total
in Months
Cost
-12
0.68
-11
0.63
-10
0.47
-9
0.54
-8
0.62
-7
0.93
-6
0.85
-5
0.55
-4
0.69
-3
0.46
-2
1.00
-1
0.43
0
0.67
1
0.63
2
0.67
3
0.93
4
0.50
5
0.98
6
0.50
7
0.67
8
0.81
9
0.67
10
0.71
11
0.00
0.65

Norm
alized
Tech
Cost
0.64
0.59
0.44
0.53
0.61
0.93
0.82
0.51
0.68
0.47
1.00
0.42
0.67
0.64
0.66
0.92
0.50
0.99
0.50
0.67
0.80
0.68
0.72
0.00
0.64

Norm
alized
Prof
Cost
0.90
0.91
0.67
0.59
0.63
0.88
1.00
0.78
0.74
0.36
0.96
0.46
0.62
0.56
0.73
0.98
0.50
0.84
0.50
0.63
0.80
0.60
0.62
0.00
0.68

Avg

ED
Visits

LOS
8.29
8.65
9.07
7.72
8.06
9.08
9.29
8.22
10.04
7.69
9.33
8.09
8.64
9.21
9.48
8.93
6.59
10.10
7.05
8.71
6.75
8.14
8.79
5.72
8.40

Per 1000
17.24
18.09
21.24
13.31
21.78
22.44
28.85
28.82
27.62
30.94
21.46
15.47
12.03
22.19
34.53
12.70
11.48
16.29
17.36
14.56
10.51
20.97
16.59
21.91
19.93

Admits
Per
1000
162.07
171.05
130.72
159.76
139.03
169.87
171.47
162.82
132.60
126.58
171.67
143.46
140.37
141.47
154.73
160.32
165.57
154.72
161.46
155.34
168.17
143.55
131.22
118.94
151.54

Readmits
Per 1000
0.16
0.18
0.15
0.31
0.16
0.26
0.21
0.22
0.11
0.19
0.21
0.19
0.19
0.21
0.18
0.16
0.21
0.19
0.22
0.17
0.16
0.24
0.22
0.18
0.19
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APPENDIX E

ITS Regression Analysis Detail
Normalized and Adjusted Total HF Cost
. itsa its_total_cost_norm pc_male pc_white mean_cci mean_age, single trperiod(0) l
> ag(1) figure posttrend
time variable: time, -12 to 11
delta: 1 unit
Regression with Newey-West standard errors
maximum lag: 1

F( 7,
Prob > F

Number of obs
16) =

=

=

24

2.62

0.0522

-----------------------------------------------------------------------------|
its_total_~m |

Newey-West
Coef. Std. Err.

t

P>|t|

[95% Conf. Interval]

-------------+---------------------------------------------------------------pc_male | -.0813916 .0389965

-2.09 0.053

-.1640604

.0012773

pc_white | .1411029 .0472786

2.98 0.009

.0408767

.2413291

mean_cci | 1.288993 .4859287

2.65 0.017

.2588704

2.319116

mean_age | -.1268248 .1059795

-1.20 0.249

-.3514914

_t | -.0080645 .0121131

-0.67 0.515

-.033743

.0978418

.017614

_x0 | .2105958 .1148896

1.83 0.085

-.0329593

.454151

_x_t0 | .012119 .0322314

0.38 0.712

-.0562085

.0804464

_cons | -4.7369 7.283367

-0.65 0.525

-20.17695

10.70315

------------------------------------------------------------------------------
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Postintervention Linear Trend: 0
Treated: _b[_t]+_b[_x_t0]
-----------------------------------------------------------------------------Linear Trend |

Coeff Std. Err.

t

P>|t| [95% Conf. Interval]

-------------+---------------------------------------------------------------Treated |

0.0041 0.0253

0.1600

0.8749

-0.0497

0.0578

-----------------------------------------------------------------------------Cumby-Huizinga test for autocorrelation (Breusch-Godfrey)
H0: variable is MA process up to order q
HA: serial correlation present at specified lags >q
----------------------------------------------------------------------------H0: q=0 (serially uncorrelated)

| H0: q=specified lag-1

HA: s.c. present at range specified

| HA: s.c. present at lag specified

-----------------------------------------+----------------------------------lags |

chi2

df

p-val | lag |

chi2

df

p-val

-----------+-----------------------------+-----+----------------------------1- 1 |

1.180

1

0.2773 | 1 |

1.180

1

0.2773

1- 2 |

1.884

2

0.3899 | 2 |

0.123

1

0.7257

1- 3 |

3.476

3

0.3239 | 3 |

0.505

1

0.4772

1- 4 |

8.360

4

0.0792 | 4 |

3.391

1

0.0655

1- 5 |

8.360

5

0.1375 | 5 |

2.065

1* 0.1507

-----------------------------------------------------------------------------
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Normalized and Adjusted HF Technical Costs
itsa its_tech_cost_norm pc_male pc_white mean_cci mean_age, single trperiod(0) lag(1
> ) figure posttrend
time variable: time, -12 to 11
delta: 1 unit
Regression with Newey-West standard errors
maximum lag: 1

F( 7,
Prob > F

Number of obs
16) =

=

=

24

3.39

0.0206

-----------------------------------------------------------------------------|

Newey-West

its_tech_c~m |

Coef. Std. Err.

t

P>|t|

[95% Conf. Interval]

-------------+---------------------------------------------------------------pc_male | -.0862635 .0391301

-2.20 0.042

-.1692155 -.0033115

pc_white | .1416851 .0465157

3.05 0.008

.0430762

.2402939

mean_cci | 1.331886 .4902058

2.72 0.015

.292696

2.371076

mean_age | -.1261176 .1049957

-1.20 0.247

-.3486986

_t | -.0052261 .0116497

-0.45 0.660

-.0299224

.0964634

.0194702

_x0 | .2041695 .1101865

1.85 0.082

-.0294154

.4377543

_x_t0 | .0121568 .0316548

0.38 0.706

-.0549485

.0792621

_cons | -4.766756 7.262495

-0.66 0.521

-20.16256

10.62905

-----------------------------------------------------------------------------Postintervention Linear Trend: 0
Treated: _b[_t]+_b[_x_t0]
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-----------------------------------------------------------------------------Linear Trend |

Coeff Std. Err.

t

P>|t| [95% Conf. Interval]

-------------+---------------------------------------------------------------Treated |

0.0069 0.0253

0.2738

0.7877

-0.0467

0.0606

-----------------------------------------------------------------------------Cumby-Huizinga test for autocorrelation (Breusch-Godfrey)
H0: variable is MA process up to order q
HA: serial correlation present at specified lags >q
----------------------------------------------------------------------------H0: q=0 (serially uncorrelated)

| H0: q=specified lag-1

HA: s.c. present at range specified

| HA: s.c. present at lag specified

-----------------------------------------+----------------------------------lags |

chi2

df

p-val | lag |

chi2

df

p-val

-----------+-----------------------------+-----+----------------------------1- 1 |

1.402

1

0.2364 | 1 |

1.402

1

0.2364

1- 2 |

2.324

2

0.3129 | 2 |

0.166

1

0.6841

1- 3 |

3.622

3

0.3053 | 3 |

0.267

1

0.6051

1- 4 |

8.617

4

0.0714 | 4 |

3.306

1

0.0690

1- 5 |

8.624

5

0.1250 | 5 |

2.057

1* 0.1515

-------------------------------------------------------Normalized and Adjusted HF Professional Costs
itsa its_prof_cost_norm pc_male pc_white mean_cci mean_age, single trperiod(0) lag(1
> ) figure posttrend

A QUANTITATIVE REVIEW OF COSTS

90

time variable: time, -12 to 11
delta: 1 unit

Regression with Newey-West standard errors
maximum lag: 1

F( 7,
Prob > F

Number of obs
16) =

=

=

24

1.66

0.1905

-----------------------------------------------------------------------------|

Newey-West

its_prof_c~m |

Coef. Std. Err.

t

P>|t|

[95% Conf. Interval]

-------------+---------------------------------------------------------------pc_male | -.0483567 .0392867

-1.23 0.236

-.1316409

.0349275

pc_white | .1321997 .0535278

2.47 0.025

.0187259

.2456735

mean_cci | .9765595 .4812447

2.03 0.059

-.0436338

1.996753

mean_age | -.1263904 .1111147

-1.14 0.272

_t | -.0252181 .0155628

-1.62 0.125

-.3619429

-.0582096

.1091622

.0077735

_x0 | .2421771 .1495381

1.62 0.125

-.0748296

.5591838

_x_t0 | .0114289 .0366845

0.31 0.759

-.0663386

.0891965

_cons | -4.374606 7.537823

-0.58 0.570

-20.35408

11.60486

-----------------------------------------------------------------------------Postintervention Linear Trend: 0
Treated: _b[_t]+_b[_x_t0]
-----------------------------------------------------------------------------Linear Trend |

Coeff Std. Err.

t

P>|t| [95% Conf. Interval]
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-------------+---------------------------------------------------------------Treated |

-0.0138 0.0259 -0.5320

0.6020

-0.0687

0.0412

-----------------------------------------------------------------------------Cumby-Huizinga test for autocorrelation (Breusch-Godfrey)
H0: variable is MA process up to order q
HA: serial correlation present at specified lags >q
----------------------------------------------------------------------------H0: q=0 (serially uncorrelated)

| H0: q=specified lag-1

HA: s.c. present at range specified

| HA: s.c. present at lag specified

-----------------------------------------+----------------------------------lags |

chi2

df

p-val | lag |

chi2

df

p-val

-----------+-----------------------------+-----+----------------------------1- 1 |

0.193

1

0.6606 | 1 |

0.193

1

0.6606

1- 2 |

0.449

2

0.7989 | 2 |

0.145

1

0.7034

1- 3 |

5.275

3

0.1527 | 3 |

3.416

1

0.0646

1- 4 |

7.931

4

0.0941 | 4 |

1.812

1

0.1782

1- 5 |

8.338

5

0.1385 | 5 |

1.841

1* 0.1748

----------------------------------------------------------------------------Normalized and Adjusted HF Cost
itsa cost_hf_norm pc_male pc_white mean_cci mean_age, single trperiod(0) lag(1) fig
> ure posttrend
time variable: time, -12 to 11
delta: 1 unit
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Regression with Newey-West standard errors
maximum lag: 1

F( 7,
Prob > F

Number of obs
16) =

=

=

24

2.70

0.0475

-----------------------------------------------------------------------------|

Newey-West

cost_hf_norm |

Coef. Std. Err.

t

P>|t|

[95% Conf. Interval]

-------------+---------------------------------------------------------------pc_male | -.0179709 .0247662

-0.73 0.479

-.0704728

.034531

pc_white | .1279522 .0390098

3.28 0.005

.0452551

.2106494

mean_cci | .8054308 .3764444

2.14 0.048

.0074044

1.603457

mean_age | -.1140815 .0696877

-1.64 0.121

-.2618127

_t | .0006367 .0127914

0.05 0.961

-.0264799
-.0179277

.0336498

.0277533

_x0 | .2297607 .1168394

1.97 0.067

.4774492

_x_t0 | -.0336032 .0189763

-1.77 0.096

-.0738311

.0066248

_cons | -6.259923 5.891737

-1.06 0.304

-18.74985

6.230001

-----------------------------------------------------------------------------Postintervention Linear Trend: 0
Treated: _b[_t]+_b[_x_t0]
-----------------------------------------------------------------------------Linear Trend |

Coeff Std. Err.

t

P>|t| [95% Conf. Interval]

-------------+---------------------------------------------------------------Treated |

-0.0330 0.0167 -1.9706

0.0663

-0.0684

0.0025

------------------------------------------------------------------------------
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Cumby-Huizinga test for autocorrelation (Breusch-Godfrey)
H0: variable is MA process up to order q
HA: serial correlation present at specified lags >q
----------------------------------------------------------------------------H0: q=0 (serially uncorrelated)

| H0: q=specified lag-1

HA: s.c. present at range specified

| HA: s.c. present at lag specified

-----------------------------------------+----------------------------------lags |

chi2

df

p-val | lag |

chi2

df

p-val

-----------+-----------------------------+-----+----------------------------1- 1 |

4.839

1

0.0278 | 1 |

4.839

1

0.0278

1- 2 |

5.121

2

0.0773 | 2 |

0.007

1

0.9336

1- 3 |

5.885

3

0.1173 | 3 |

0.301

1

0.5835

1- 4 |

7.393

4

0.1165 | 4 |

0.312

1

0.5763

1- 5 |

8.381

5

0.1365 | 5 |

1.319

1* 0.2508

----------------------------------------------------------------------------Normalized and Adjusted HF Surgical Costs
itsa cost_surgical_norm pc_male pc_white mean_cci mean_age, single trperiod(0) lag(1
> ) figure posttrend
time variable: time, -12 to 11
delta: 1 unit
Regression with Newey-West standard errors
maximum lag: 1

F( 7,
Prob > F

Number of obs
16) =

=

0.0947

2.17

=

24
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-----------------------------------------------------------------------------|

Newey-West

cost_surgi~m |

Coef. Std. Err.

t

P>|t|

[95% Conf. Interval]

-------------+---------------------------------------------------------------pc_male | -.0011555

.007438

-0.16 0.878

-.0169235

.0146124

pc_white | .0009533 .0140324

0.07 0.947

-.0287941

.0307007

mean_cci | -.0212267 .1091551

-0.19 0.848

-.2526252

.2101718

mean_age | -.0243314 .0296652

-0.82 0.424

-.0872189

.038556

_t | .025299 .0232981

1.09 0.294

-.0240908

.0746889

_x0 | -.0349692 .1740704

-0.20 0.843

-.4039819

_x_t0 | -.0678776 .0305108

-2.22 0.041

-.1325575 -.0031977

_cons | 1.92134 1.526902

1.26 0.226

-1.315548

.3340435

5.158229

-----------------------------------------------------------------------------Postintervention Linear Trend: 0
Treated: _b[_t]+_b[_x_t0]
-----------------------------------------------------------------------------Linear Trend |

Coeff Std. Err.

t

P>|t| [95% Conf. Interval]

-------------+---------------------------------------------------------------Treated |

-0.0426 0.0131 -3.2494

0.0050

-0.0704 -0.0148

Cumby-Huizinga test for autocorrelation (Breusch-Godfrey)
H0: variable is MA process up to order q
HA: serial correlation present at specified lags >q
-----------------------------------------------------------------------------
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| H0: q=specified lag-1

HA: s.c. present at range specified

| HA: s.c. present at lag specified

-----------------------------------------+----------------------------------lags |

chi2

df

p-val | lag |

chi2

df

p-val

-----------+-----------------------------+-----+----------------------------1- 1 |

0.000

1

0.9831 | 1 |

0.000

1

0.9831

1- 2 |

0.034

2

0.9831 | 2 |

0.033

1

0.8569

1- 3 |

4.940

3

0.1762 | 3 |

4.577

1

0.0324

1- 4 |

7.155

4

0.1279 | 4 |

0.537

1

0.4636

1- 5 |

8.042

5

0.1540 | 5 |

1.212

1

0.2710

----------------------------------------------------------------------------Normalized and Adjusted HF Non-Surgical Costs
itsa cost_nonsurgical_norm pc_male pc_white mean_cci mean_age, single trperiod(0) la
> g(1) figure posttrend
time variable: time, -12 to 11
delta: 1 unit
Regression with Newey-West standard errors
maximum lag: 1

F( 7,
Prob > F

Number of obs
16) =

=

=

5.01

0.0037

-----------------------------------------------------------------------------|
cost_nonsu~m |

Newey-West
Coef. Std. Err.

t

P>|t|

[95% Conf. Interval]

-------------+----------------------------------------------------------------
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pc_male | .0609993 .0378871

1.61 0.127

-.0193176

.1413163

pc_white | .0435495 .1037644

0.42 0.680

-.1764212

.2635202

mean_cci | .5176415 .4847526

1.07 0.301

-.5099881

1.545271

mean_age | -.1232884 .1191868

-1.03 0.316

_t | .0009418

.017463

0.05 0.958

_x0 | .2536298 .1519112
_x_t0 | -.0969052

.039319

_cons | -1.997992 6.995061

-.3759532

-.036078

.1293764

.0379617

1.67 0.114

-.0684075

-2.46 0.025

-.1802578 -.0135525

-0.29 0.779

.5756672

-16.82686

12.83087

-----------------------------------------------------------------------------Postintervention Linear Trend: 0
Treated: _b[_t]+_b[_x_t0]
-----------------------------------------------------------------------------Linear Trend |

Coeff Std. Err.

t

P>|t| [95% Conf. Interval]

-------------+---------------------------------------------------------------Treated |

-0.0960 0.0283 -3.3877

0.0038

-0.1560 -0.0359

Cumby-Huizinga test for autocorrelation (Breusch-Godfrey)
H0: variable is MA process up to order q
HA: serial correlation present at specified lags >q
----------------------------------------------------------------------------H0: q=0 (serially uncorrelated)
HA: s.c. present at range specified

| H0: q=specified lag-1
| HA: s.c. present at lag specified

-----------------------------------------+----------------------------------lags |

chi2

df

p-val | lag |

chi2

df

p-val
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-----------+-----------------------------+-----+----------------------------1- 1 |

0.319

1

0.5721 | 1 |

0.319

1

0.5721

1- 2 |

1.034

2

0.5964 | 2 |

0.436

1

0.5091

1- 3 |

7.148

3

0.0673 | 3 |

5.184

1

0.0228

1- 4 |

11.498

4

0.0215 | 4 |

0.146

1* 0.7020

1- 5 |

11.965

5

0.0353 | 5 |

0.003

1

0.9531

----------------------------------------------------------------------------Normalized and Adjusted VAD Costs
itsa cost_vad_norm pc_male pc_white mean_cci mean_age, single trperiod(0) lag(1) fi
> gure posttrend
time variable: time, -12 to 11
delta: 1 unit
Regression with Newey-West standard errors
maximum lag: 1

F( 7,
Prob > F

Number of obs
16) =

=

=

24

15.00

0.0000

-----------------------------------------------------------------------------|
cost_vad_n~m |

Newey-West
Coef. Std. Err.

t

P>|t|

[95% Conf. Interval]

-------------+---------------------------------------------------------------pc_male | -.0014634 .0019724

-0.74 0.469

-.0056448

.0027179

pc_white | -.0014577 .0022058

-0.66 0.518

-.0061338

.0032183

mean_cci | .0758805 .0234349

3.24 0.005

.0262007

.1255602

mean_age | -.002439 .0060729

-0.40 0.693

-.0153129

.0104349
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_t | -.0177346 .0122969

98

-1.44 0.169

-.043803

.0083337

_x0 | -.2272358 .1304271

-1.74 0.101

-.5037288

.0492572

_x_t0 | .0376478 .0213525

1.76 0.097

-.0076175

.0829131

_cons | .7122748

.19632

3.63 0.002

.296095

1.128455

-----------------------------------------------------------------------------Postintervention Linear Trend: 0
Treated: _b[_t]+_b[_x_t0]
-----------------------------------------------------------------------------Linear Trend |

Coeff Std. Err.

t

P>|t| [95% Conf. Interval]

-------------+---------------------------------------------------------------Treated |

0.0199 0.0173

1.1523

0.2661

-0.0167

0.0565

-----------------------------------------------------------------------------Cumby-Huizinga test for autocorrelation (Breusch-Godfrey)
H0: variable is MA process up to order q
HA: serial correlation present at specified lags >q
----------------------------------------------------------------------------H0: q=0 (serially uncorrelated)

| H0: q=specified lag-1

HA: s.c. present at range specified

| HA: s.c. present at lag specified

-----------------------------------------+----------------------------------lags |

chi2

df

p-val | lag |

chi2

df

p-val

-----------+-----------------------------+-----+----------------------------1- 1 |

0.377

1

0.5390 | 1 |

0.377

1

0.5390

1- 2 |

4.101

2

0.1287 | 2 |

4.027

1

0.0448
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1- 3 |

4.939

3

0.1763 | 3 |

0.314

1

0.5753

1- 4 |

5.810

4

0.2138 | 4 |

0.035

1

0.8507

1- 5 |

6.070

5

0.2995 | 5 |

0.141

1* 0.7075

-------------------------------------------------------------------------ED Visits Per 1000
itsa ed_per1000 pc_male pc_white mean_cci mean_age, single trperiod(0) lag(1) figure
posttrend
time variable: time, -12 to 11
delta: 1 unit
Regression with Newey-West standard errors
maximum lag: 1

F( 7,
Prob > F

Number of obs
16) =

=

=

24

2.00

0.1190

-----------------------------------------------------------------------------|
ed_per1000 |

Newey-West
Coef. Std. Err.

t

P>|t|

[95% Conf. Interval]

-------------+---------------------------------------------------------------pc_male | .8503709 1.233565

0.69 0.500

-1.76467

pc_white | -.3517546 2.340592

-0.15 0.882

-5.313588

4.610079

mean_cci | -19.17529 20.29494

-0.94 0.359

-62.19866

23.84807

mean_age | -1.341422

-0.53 0.601

-6.669826

3.986982

2.51351

-.4483589

3.465412

_t | .8942306 .6333252

1.41 0.177

2.23682

_x0 | -8.611562 6.379412

-1.35 0.196

-22.13531

4.912187

_x_t0 | -1.751865 1.497513

-1.17 0.259

-4.926449

1.42272
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_cons | 174.3749 295.7684

100
0.59 0.564

-452.6262

801.376

-----------------------------------------------------------------------------Postintervention Linear Trend: 0
Treated: _b[_t]+_b[_x_t0]
-----------------------------------------------------------------------------Linear Trend |

Coeff Std. Err.

t

P>|t| [95% Conf. Interval]

-------------+---------------------------------------------------------------Treated |

-0.8576 1.0977 -0.7813

0.4460

-3.1847

1.4695

-----------------------------------------------------------------------------. actest, lag(5)
Cumby-Huizinga test for autocorrelation (Breusch-Godfrey)
H0: variable is MA process up to order q
HA: serial correlation present at specified lags >q
----------------------------------------------------------------------------H0: q=0 (serially uncorrelated)

| H0: q=specified lag-1

HA: s.c. present at range specified

| HA: s.c. present at lag specified

-----------------------------------------+----------------------------------lags |

chi2

df

p-val | lag |

chi2

df

p-val

-----------+-----------------------------+-----+----------------------------1- 1 |

1.154

1

0.2827 | 1 |

1.154

1

0.2827

1- 2 |

5.043

2

0.0803 | 2 |

3.482

1

0.0620

1- 3 |

8.392

3

0.0386 | 3 |

3.926

1

0.0475

1- 4 |

8.522

4

0.0742 | 4 |

0.302

1

0.5828

A QUANTITATIVE REVIEW OF COSTS
1- 5 |

12.187

5
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0.0323 | 5 |

0.042

1

0.8367

----------------------------------------------------------------------------Test allows predetermined regressors/instruments
Test requires conditional homoskedasticity

. ge adjusted= _s_ed_per1000_pred
. drop _t _x0 _x_t0 _s_ed_per1000_pred
----------------------------------------------------------------------------Admissions Per 1000
itsa admit_per1000 pc_male pc_white mean_cci mean_age, single trperiod(0) lag(1)
figure posttrend
time variable: time, -12 to 11
delta: 1 unit

Regression with Newey-West standard errors
maximum lag: 1

F( 7,
Prob > F

Number of obs
16) =

=

=

24

0.52

0.8103

-----------------------------------------------------------------------------|
admit_p~1000 |

Newey-West
Coef. Std. Err.

t

P>|t|

[95% Conf. Interval]

-------------+---------------------------------------------------------------pc_male | -.1235779 2.511661

-0.05 0.961

pc_white | 7.00518 6.412629

1.09 0.291

-5.448062
-6.588986

5.200906
20.59935
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mean_cci | 39.37776 50.59206

0.78 0.448

mean_age | -4.232948 9.132943

-0.46 0.649

_t | -1.27521 1.031745

-1.24 0.234

-67.87261

146.6281

-23.59392

-3.462411

15.12803

.9119911

_x0 | 15.73977 13.53132

1.16 0.262

-12.94535

44.42489

_x_t0 | .2868107 3.226127

0.09 0.930

-6.552274

7.125895

_cons | -368.9929 741.5517

-0.50 0.626

-1941.012

1203.027

-----------------------------------------------------------------------------Postintervention Linear Trend: 0
Treated: _b[_t]+_b[_x_t0]
-----------------------------------------------------------------------------Linear Trend |

Coeff Std. Err.

t

P>|t| [95% Conf. Interval]

-------------+---------------------------------------------------------------Treated |

-0.9884 2.7224 -0.3631

0.7213

-6.7597

4.7829

-----------------------------------------------------------------------------. actest, lag(5)
Cumby-Huizinga test for autocorrelation (Breusch-Godfrey)
H0: variable is MA process up to order q
HA: serial correlation present at specified lags >q
----------------------------------------------------------------------------H0: q=0 (serially uncorrelated)
HA: s.c. present at range specified

| H0: q=specified lag-1
| HA: s.c. present at lag specified

-----------------------------------------+----------------------------------lags |

chi2

df

p-val | lag |

chi2

df

p-val
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-----------+-----------------------------+-----+----------------------------1- 1 |

0.001

1

0.9765 | 1 |

0.001

1

0.9765

1- 2 |

0.082

2

0.9599 | 2 |

0.080

1

0.7776

1- 3 |

3.895

3

0.2730 | 3 |

3.863

1

0.0494

1- 4 |

3.910

4

0.4183 | 4 |

0.046

1

0.8303

1- 5 |

4.520

5

0.4772 | 5 |

0.118

1

0.7315

----------------------------------------------------------------------------Test allows predetermined regressors/instruments
Test requires conditional homoskedasticity
. ge adjusted=_s_admit_per1000_pred
. drop _t _x0 _x_t0 _s_admit_per1000_pred
----------------------------------------------------------------------------Readmits Per 1000
itsa readmit_rate pc_male pc_white mean_cci mean_age, single trperiod(0) lag(1) figure
posttrend
time variable: time, -12 to 11
delta: 1 unit
Regression with Newey-West standard errors
maximum lag: 1

F( 7,
Prob > F

Number of obs
16) =

=

=

0.58

0.7588

-----------------------------------------------------------------------------|
readmit_rate |

Newey-West
Coef. Std. Err.

t

P>|t|

[95% Conf. Interval]

24
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-------------+---------------------------------------------------------------pc_male | -.0058888 .0080034

-0.74 0.473

-.0228553

.0110776

pc_white | .0160214 .0139683

1.15 0.268

-.0135901

.0456329

mean_cci | -.0547663 .0935184

-0.59 0.566

-.2530164

.1434838

mean_age | .0034991 .0149554

0.23 0.818

-.028205

.0352032

_t | -.0005907 .0026267

-0.22 0.825

-.006159

.0049776

_x0 | .005454

0.20 0.842

-.0517857

.0626937

.027001

_x_t0 | .0081468 .0090746
_cons | -.7448158

0.90 0.383

1.4998

-0.50 0.626

-.0110904
-3.92425

.0273841
2.434619

-----------------------------------------------------------------------------Postintervention Linear Trend: 0
Treated: _b[_t]+_b[_x_t0]
-----------------------------------------------------------------------------Linear Trend |

Coeff Std. Err.

t

P>|t| [95% Conf. Interval]

-------------+---------------------------------------------------------------Treated |

0.0076 0.0073

1.0285

0.3190

-0.0080

0.0231

-----------------------------------------------------------------------------. actest, lag(5)
Cumby-Huizinga test for autocorrelation (Breusch-Godfrey)
H0: variable is MA process up to order q
HA: serial correlation present at specified lags >q
----------------------------------------------------------------------------H0: q=0 (serially uncorrelated)

| H0: q=specified lag-1

A QUANTITATIVE REVIEW OF COSTS
HA: s.c. present at range specified
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| HA: s.c. present at lag specified

-----------------------------------------+----------------------------------lags |

chi2

df

p-val | lag |

chi2

df

p-val

-----------+-----------------------------+-----+----------------------------1- 1 |

1.163

1

0.2808 | 1 |

1.163

1

0.2808

1- 2 |

1.163

2

0.5590 | 2 |

0.001

1

0.9726

1- 3 |

5.623

3

0.1315 | 3 |

3.947

1

0.0470

1- 4 |

5.683

4

0.2241 | 4 |

0.370

1* 0.5428

1- 5 |

8.327

5

0.1391 | 5 |

0.539

1

0.4630

----------------------------------------------------------------------------Test allows predetermined regressors/instruments
Test requires conditional homoskedasticity
* Eigenvalues adjusted to make matrix positive semidefinite

. ge adjusted=_s_readmit_rate_pred
. drop _t _x0 _x_t0 _s_readmit_rate_pred
-----------------------------------------------------------------------------Mean LOS
itsa mean_los pc_male pc_white mean_cci mean_age, single trperiod(0) lag(1) figure
posttrend
time variable: time, -12 to 11
delta: 1 unit
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Regression with Newey-West standard errors
maximum lag: 1

F( 7,

Number of obs
16) =

Prob > F

=

=

24

2.61

0.0532

-----------------------------------------------------------------------------|

Newey-West

mean_los |

Coef. Std. Err.

t

P>|t|

[95% Conf. Interval]

-------------+---------------------------------------------------------------pc_male | -.2270253 .1899313

-1.20 0.249

pc_white | .370852 .3211162

1.15 0.265

-.6296615
-.3098839

mean_cci | 3.534379 3.549748

1.00 0.334

mean_age | -.4097409 .4059074

-1.01 0.328

_t | -.0045016 .0640854
_x0 | .6685449 .6366554

-0.07 0.945

.175611
1.051588

-3.990751

11.05951

-1.270226

-.1403565

.4507444

.1313534

1.05 0.309

-.6811041

2.018194

_x_t0 | -.1168599

.175714

-0.67 0.515

-.489357

.2556371

_cons | -.674593

50.2011

-0.01 0.989

-107.0962

105.747

-----------------------------------------------------------------------------Postintervention Linear Trend: 0
Treated: _b[_t]+_b[_x_t0]
-----------------------------------------------------------------------------Linear Trend |

Coeff Std. Err.

t

P>|t| [95% Conf. Interval]

-------------+---------------------------------------------------------------Treated |

-0.1214 0.1339 -0.9061

0.3783

-0.4053

0.1626

------------------------------------------------------------------------------
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. actest, lag(5)
Cumby-Huizinga test for autocorrelation (Breusch-Godfrey)
H0: variable is MA process up to order q
HA: serial correlation present at specified lags >q
----------------------------------------------------------------------------H0: q=0 (serially uncorrelated)

| H0: q=specified lag-1

HA: s.c. present at range specified

| HA: s.c. present at lag specified

-----------------------------------------+----------------------------------lags |

chi2

df

p-val | lag |

chi2

df

p-val

-----------+-----------------------------+-----+----------------------------1- 1 |

5.582

1

0.0182 | 1 |

5.582

1

0.0182

1- 2 |

7.493

2

0.0236 | 2 |

0.009

1

0.9251

1- 3 |

9.153

3

0.0273 | 3 |

0.002

1

0.9669

1- 4 |

10.286

4

0.0359 | 4 |

0.693

1

0.4053

1- 5 |

11.183

5

0.0479 | 5 |

0.111

1

0.7390

----------------------------------------------------------------------------Test allows predetermined regressors/instruments
Test requires conditional homoskedasticity
. ge adjusted=_s_mean_los_pred
. drop _t _x0 _x_t0 _s_mean_los_pred

